1
|
García-Loredo JA, Santoyo-Suarez MG, Rodríguez-Nuñez O, Benitez Chao DF, Garza-Treviño EN, Zapata-Morin PA, Padilla-Rivas GR, Islas JF. Is the Cis-Element CACCC-Box a Master Regulatory Element during Cardiovascular Disease? A Bioinformatics Approach from the Perspective of the Krüppel-like Family of Transcription Factors. Life (Basel) 2024; 14:493. [PMID: 38672763 PMCID: PMC11051458 DOI: 10.3390/life14040493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Revised: 04/03/2024] [Accepted: 04/09/2024] [Indexed: 04/28/2024] Open
Abstract
The CACCC-box motif emerges as a pivotal cis-regulatory element implicated in diverse developmental processes and diseases, particularly cardiovascular diseases (CVDs). This study centers on the intricate interplay between the CACCC-box and its binding proteins such as: the Krüppel-Like Family (KLF) of transcription factors as primary effectors in the context of CVDs. Our analysis was through a bioinformatics approach, which revealed significant transcriptional activity among KLF subgroup 2, exhibiting the highest number of interactions focusing on the established roles: pluripotency, cancer, and cardiovascular development and diseases. Our analysis reveals KLF's interactions with GATA4, MEF2C, NKX2.5 and other ~90 potential genes that participate in the regulation of the hypertrophic environment (or CVDs' Environment). Also, the GO analysis showed that genes containing the motif CACCC were enriched for multiple CVDs; in combination with STRING analysis, these results pointed to a link between KLFs and these diseases. The analysis further identifies other potential CACCC-box binding factors, such as SP family members, WT1, VEZF1, and -SALL4, which are implicated in cardiac contraction, remodeling, and inflammation processes.
Collapse
Affiliation(s)
- Juan Andrés García-Loredo
- Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico; (J.A.G.-L.); (M.G.S.-S.); (O.R.-N.); (D.F.B.C.); (E.N.G.-T.); (G.R.P.-R.)
- Laboratorio de Micología y Fitopatología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Nuevo León, Mexico;
| | - Michelle G. Santoyo-Suarez
- Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico; (J.A.G.-L.); (M.G.S.-S.); (O.R.-N.); (D.F.B.C.); (E.N.G.-T.); (G.R.P.-R.)
| | - Oscar Rodríguez-Nuñez
- Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico; (J.A.G.-L.); (M.G.S.-S.); (O.R.-N.); (D.F.B.C.); (E.N.G.-T.); (G.R.P.-R.)
| | - Diego Francisco Benitez Chao
- Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico; (J.A.G.-L.); (M.G.S.-S.); (O.R.-N.); (D.F.B.C.); (E.N.G.-T.); (G.R.P.-R.)
| | - Elsa N. Garza-Treviño
- Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico; (J.A.G.-L.); (M.G.S.-S.); (O.R.-N.); (D.F.B.C.); (E.N.G.-T.); (G.R.P.-R.)
| | - Patricio Adrián Zapata-Morin
- Laboratorio de Micología y Fitopatología, Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León, San Nicolás de los Garza 66451, Nuevo León, Mexico;
| | - Gerardo R. Padilla-Rivas
- Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico; (J.A.G.-L.); (M.G.S.-S.); (O.R.-N.); (D.F.B.C.); (E.N.G.-T.); (G.R.P.-R.)
| | - Jose Francisco Islas
- Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey 64460, Nuevo León, Mexico; (J.A.G.-L.); (M.G.S.-S.); (O.R.-N.); (D.F.B.C.); (E.N.G.-T.); (G.R.P.-R.)
| |
Collapse
|
2
|
Zhang Z, Chen L, Zhang H, Xiao W, Yang J, Huang J, Hu Q, Jin K, Hong Y. Genetic correlations and causal relationships between cardio-metabolic traits and sepsis. Sci Rep 2024; 14:5718. [PMID: 38459230 PMCID: PMC10923865 DOI: 10.1038/s41598-024-56467-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Accepted: 03/06/2024] [Indexed: 03/10/2024] Open
Abstract
Cardio-metabolic traits have been reported to be associated with the development of sepsis. It is, however, unclear whether these co-morbidities reflect causal associations, shared genetic heritability, or are confounded by environmental factors. We performed three analyses to explore the relationships between cardio-metabolic traits and sepsis. Mendelian randomization (MR) study to evaluate the causal effects of multiple cardio-metabolic traits on sepsis. Global genetic correlation analysis to explore the correlations between cardio-metabolic traits and sepsis. Local genetic correlation (GC) analysis to explore shared genetic heritability between cardio-metabolic traits and sepsis. Some loci were further examined for related genes responsible for the causal relationships. Genetic associations were obtained from the UK Biobank data or published large-scale genome-wide association studies with sample sizes between 200,000 to 750,000. In MR, we found causality between BMI and sepsis (OR: 1.53 [1.4-1.67]; p < 0.001). Body mass index (BMI), which is confirmed by sensitivity analyses and multivariable MR adjusting for confounding factors. Global GC analysis showed a significant correlation between BMI and sepsis (rg = 0.55, p < 0.001). More cardio-metabolic traits were identified to be correlated to the sepsis onset such as CRP (rg = 0.37, p = 0.035), type 2 diabetes (rg = 0.33, p < 0.001), HDL (rg = - 0.41, p < 0.001), and coronary artery disease (rg = 0.43, p < 0.001). Local GC revealed some shared genetic loci responsible for the causality. The top locus 1126 was located at chromosome 7 and comprised genes HIBADH, JAZF1, and CREB5. The present study provides evidence for an independent causal effect of BMI on sepsis. Further detailed analysis of the shared genetic heritability between cardio-metabolic traits and sepsis provides the opportunity to improve the preventive strategies for sepsis.
Collapse
Affiliation(s)
- Zhongheng Zhang
- Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China.
| | - Lin Chen
- Neurological Intensive Care Unit, Department of Neurosurgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
| | - Haoyang Zhang
- School of Computer Science and Engineering, Sun Yat-Sen University, Guangzhou, China
| | - Wei Xiao
- Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China
| | - Jie Yang
- Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China
| | - Jiajie Huang
- Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China
| | - Qichao Hu
- Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China
| | - Ketao Jin
- Department of Gastrointestinal, Colorectal and Anal Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang, China
| | - Yucai Hong
- Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China
| |
Collapse
|
3
|
Alboali H, Moradi MH, Khaltabadi Farahani AH, Mohammadi H. Genome-wide association study for body weight and feed consumption traits in Japanese quail using Bayesian approaches. Poult Sci 2024; 103:103208. [PMID: 37980758 PMCID: PMC10663954 DOI: 10.1016/j.psj.2023.103208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 10/12/2023] [Accepted: 10/13/2023] [Indexed: 11/21/2023] Open
Abstract
The aim of this study was to perform a genome-wide association study (GWAS) based on Bayes A and Bayes B statistical methods to identify genomic loci and candidate genes associated with body weight gain, feed intake, and feed conversion ratio in Japanese quail. For this purpose, genomic data obtained from Illumina iSelect 4K quail SNP chip were utilized. After implementing various quality control steps, genotype data from a total of 875 birds for 2,015 SNP markers were used for subsequent analyses. The Bayesian analyses were performed using hibayes package in R (version 4.3.1) and Gibbs sampling algorithm. The results of the analyses showed that Bayes A accounted for 11.43, 11.65, and 11.39% of the phenotypic variance for body weight gain, feed intake, and feed conversion ratio, respectively, while the variance explained by Bayes B was 7.02, 8.61, and 6.48%, respectively. Therefore, in the current study, results obtained from Bayes A were used for further analyses. In order to perform the gene enrichment analysis and to identify the functional pathways and classes of genes that are over-represented in a large set of genes associated with each trait, all markers that accounted for more than 0.1% of the phenotypic variance for each trait were used. The results of this analysis revealed a total of 23, 38, and 14 SNP markers associated with body weight gain, feed intake, and feed conversion ratio in Japanese quail, respectively. The results of the gene enrichment analysis led to the identification of biological pathways (and candidate genes) related to lipid phosphorylation (TTC7A gene) and cell junction (FGFR4 and FLRT2 genes) associated with body weight gain, calcium signaling pathway (ADCY2 and CAMK1D genes) associated with feed intake, and glycerolipid metabolic process (LIPC gene), lipid metabolic process (ADGRF5 and ESR1 genes), and glutathione transferase (GSTK1 gene) associated with feed conversion ratio. Overall, the findings of this study can provide valuable insights into the genetic architecture of growth and feed consumption traits in Japanese quail.
Collapse
Affiliation(s)
- Hassan Alboali
- Department of Animal Science, Faculty of Agriculture and Environment, Arak University, 38156-8-8349 Arak, Iran
| | - Mohammad Hossein Moradi
- Department of Animal Science, Faculty of Agriculture and Environment, Arak University, 38156-8-8349 Arak, Iran.
| | | | - Hossein Mohammadi
- Department of Animal Science, Faculty of Agriculture and Environment, Arak University, 38156-8-8349 Arak, Iran
| |
Collapse
|
4
|
Aberra YT, Ma L, Björkegren JLM, Civelek M. Predicting mechanisms of action at genetic loci associated with discordant effects on type 2 diabetes and abdominal fat accumulation. eLife 2023; 12:e79834. [PMID: 37326626 PMCID: PMC10275637 DOI: 10.7554/elife.79834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 05/31/2023] [Indexed: 06/17/2023] Open
Abstract
Obesity is a major risk factor for cardiovascular disease, stroke, and type 2 diabetes (T2D). Excessive accumulation of fat in the abdomen further increases T2D risk. Abdominal obesity is measured by calculating the ratio of waist-to-hip circumference adjusted for the body-mass index (WHRadjBMI), a trait with a significant genetic inheritance. Genetic loci associated with WHRadjBMI identified in genome-wide association studies are predicted to act through adipose tissues, but many of the exact molecular mechanisms underlying fat distribution and its consequences for T2D risk are poorly understood. Further, mechanisms that uncouple the genetic inheritance of abdominal obesity from T2D risk have not yet been described. Here we utilize multi-omic data to predict mechanisms of action at loci associated with discordant effects on abdominal obesity and T2D risk. We find six genetic signals in five loci associated with protection from T2D but also with increased abdominal obesity. We predict the tissues of action at these discordant loci and the likely effector Genes (eGenes) at three discordant loci, from which we predict significant involvement of adipose biology. We then evaluate the relationship between adipose gene expression of eGenes with adipogenesis, obesity, and diabetic physiological phenotypes. By integrating these analyses with prior literature, we propose models that resolve the discordant associations at two of the five loci. While experimental validation is required to validate predictions, these hypotheses provide potential mechanisms underlying T2D risk stratification within abdominal obesity.
Collapse
Affiliation(s)
- Yonathan Tamrat Aberra
- Department of Biomedical Engineering, University of VirginiaCharlottesvilleUnited States
- Center for Public Health Genomics, University of VirginiaCharlottesvilleUnited States
| | - Lijiang Ma
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount SinaiNew YorkUnited States
| | - Johan LM Björkegren
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount SinaiNew YorkUnited States
- Department of Medicine, Karolinska Institutet, HuddingeStockholmSweden
| | - Mete Civelek
- Department of Biomedical Engineering, University of VirginiaCharlottesvilleUnited States
- Center for Public Health Genomics, University of VirginiaCharlottesvilleUnited States
| |
Collapse
|
5
|
Mameri A, Côté J. JAZF1: A metabolic actor subunit of the NuA4/TIP60 chromatin modifying complex. Front Cell Dev Biol 2023; 11:1134268. [PMID: 37091973 PMCID: PMC10119425 DOI: 10.3389/fcell.2023.1134268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 03/29/2023] [Indexed: 04/25/2023] Open
Abstract
The multisubunit NuA4/TIP60 complex is a lysine acetyltransferase, chromatin modifying factor and gene co-activator involved in diverse biological processes. The past decade has seen a growing appreciation for its role as a metabolic effector and modulator. However, molecular insights are scarce and often contradictory, underscoring the need for further mechanistic investigation. A particularly exciting route emerged with the recent identification of a novel subunit, JAZF1, which has been extensively linked to metabolic homeostasis. This review summarizes the major findings implicating NuA4/TIP60 in metabolism, especially in light of JAZF1 as part of the complex.
Collapse
|
6
|
Ustianowski P, Malinowski D, Czerewaty M, Safranow K, Tarnowski M, Dziedziejko V, Pawlik A. THADA, SDHAF4, and MACF1 Gene Polymorphisms and Placental Expression in Women with Gestational Diabetes. Genes (Basel) 2022; 14:genes14010083. [PMID: 36672824 PMCID: PMC9859259 DOI: 10.3390/genes14010083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 12/13/2022] [Accepted: 12/22/2022] [Indexed: 12/29/2022] Open
Abstract
Gestational diabetes mellitus (GDM) is a metabolic disorder in pregnant women leading to various complications. Consequently, factors predisposing its development are being sought. Previous studies have shown that the pathogenesis of GDM is similar to that of type 2 diabetes, and it is therefore thought that the two diseases may have a common genetic basis. The aim of this study was to examine the associations between thyroid adenoma-associated (THADA) rs7578597 T>C, succinate dehydrogenase complex assembly factor 4 (SDHAF4) rs1048886 A>G, and microtubule-actin crosslinking factor 1 (MACF1) rs2296172 A>G gene polymorphisms and the risk of GDM development as well as selected clinical parameters in women with GDM. We also examined the expression of these genes in the placenta of women with and without GDM in association with clinical parameters. This case-control study included 272 pregnant women with GDM and 348 pregnant women with normal glucose tolerance. There were no statistically significant differences in the distribution of the THADA rs7578597 T>C, SDHAF4 rs1048886 A>G, and MACF1 rs2296172 A>G gene polymorphisms between pregnant control women and women with GDM. The associations between clinical parameters such as body mass before pregnancy, body mass at birth, body mass increase during pregnancy, BMI before pregnancy, BMI at birth, BMI increase during pregnancy, glycated hemoglobin (HbA1c), daily insulin requirement, childbirth time, and newborn body mass and APGAR score, and the THADA rs7578597 T>C, SDHAF4 rs1048886 A>G, and MACF1 rs2296172 A>G genotypes were statistically non-significant. We only observed lower values of body mass before pregnancy and body mass at birth in women with the SDHAF4 rs1048886 AG genotype in comparison with AA genotype carriers. There was no statistically significant difference in the expression of THADA, SDHAF4, and MACF1 genes in the placenta between women with GDM and healthy women. There were also no statistically significant correlations between THADA, SDHAF4, and MACF1 gene expression in the placenta and clinical parameters. The results of our study suggest that THADA rs7578597 T>C, SDHAF4 rs1048886 A>G, and MACF1 rs2296172 A>G gene polymorphisms are not significant factors associated with GDM onset. In addition, SDHAF4 rs1048886 A>G may be associated with body mass before pregnancy and body mass at birth in pregnant women.
Collapse
Affiliation(s)
| | - Damian Malinowski
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland
| | - Michał Czerewaty
- Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland
| | - Krzysztof Safranow
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
| | - Maciej Tarnowski
- Department of Physiology in Health Sciences, Pomeranian Medical University, 70-210 Szczecin, Poland
| | - Violetta Dziedziejko
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland
| | - Andrzej Pawlik
- Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland
| |
Collapse
|
7
|
张 佳, 薛 薇, 章 述, 朱 雅, 阳 成, 高 月, 石 凌, 黄 文. [TSPAN8 is involved in lipid metabolism in non-alcoholic fatty liver disease in mice]. NAN FANG YI KE DA XUE XUE BAO = JOURNAL OF SOUTHERN MEDICAL UNIVERSITY 2022; 42:705-711. [PMID: 35673914 PMCID: PMC9178638 DOI: 10.12122/j.issn.1673-4254.2022.05.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To investigate the changes of tetraspanin 8 (TSPAN8) expression levels and its role in lipid metabolism during the development of non-alcoholic fatty liver disease (NAFLD). METHODS Thirty male C57BL/6J mice were randomly divided into normal diet group and high-fat diet (HFD) group (n=15), and after feeding for 1, 3, and 6 months, the expression levels of TSPAN8 in the liver tissues of the mice were detected with Western blotting. In a HepG2 cell model of NAFLD induced by free fatty acids (FFA), the effect of TSPAN8 overexpression on lipid accumulation was examined using Oil Red O staining and an automated biochemical analyzer, and the mRNA expressions of the key genes involved in lipid metabolism were detected using qRT-PCR. RESULTS Western blotting showed that compared with that in mice with normal feeding, the expression of TSPAN8 was significantly decreased in the liver tissues of mice with HFD feeding for 3 and 6 months (P < 0.05). In HepG2 cells, treatment with FFA significantly decreased the expression of TSPAN8 at both the mRNA and protein levels (P < 0.01). TSPAN8 overexpression in FFA-treated cells showed significantly lowered intracellular triglyceride levels (P < 0.001) and obviously reduced mRNA expression of fatty acid transport protein 5 (FATP5) (P < 0.01). The expression of FATP5 was significantly increased in FFA-treated cells as compared with the control cells (P < 0.001). CONCLUSION TSPAN8 is involved in lipid metabolism in NAFLD, and overexpression of TSPAN8 may inhibit cellular lipid deposition by reducing the expression of FATP5.
Collapse
Affiliation(s)
- 佳 张
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - 薇 薛
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - 述军 章
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - 雅莉 朱
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - 成 阳
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - 月 高
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - 凌枫 石
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - 文祥 黄
- />重庆医科大学附属第一医院感染科,重庆 400016Department of Infectious Diseases, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| |
Collapse
|
8
|
Sánchez-Maldonado JM, Collado R, Cabrera-Serrano AJ, Ter Horst R, Gálvez-Montosa F, Robles-Fernández I, Arenas-Rodríguez V, Cano-Gutiérrez B, Bakker O, Bravo-Fernández MI, García-Verdejo FJ, López JAL, Olivares-Ruiz J, López-Nevot MÁ, Fernández-Puerta L, Cózar-Olmo JM, Li Y, Netea MG, Jurado M, Lorente JA, Sánchez-Rovira P, Álvarez-Cubero MJ, Sainz J. Type 2 Diabetes-Related Variants Influence the Risk of Developing Prostate Cancer: A Population-Based Case-Control Study and Meta-Analysis. Cancers (Basel) 2022; 14:cancers14102376. [PMID: 35625981 PMCID: PMC9139180 DOI: 10.3390/cancers14102376] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 04/26/2022] [Accepted: 04/29/2022] [Indexed: 02/06/2023] Open
Abstract
In this study, we have evaluated whether 57 genome-wide association studies (GWAS)-identified common variants for type 2 diabetes (T2D) influence the risk of developing prostate cancer (PCa) in a population of 304 Caucasian PCa patients and 686 controls. The association of selected single nucleotide polymorphisms (SNPs) with the risk of PCa was validated through meta-analysis of our data with those from the UKBiobank and FinnGen cohorts, but also previously published genetic studies. We also evaluated whether T2D SNPs associated with PCa risk could influence host immune responses by analysing their correlation with absolute numbers of 91 blood-derived cell populations and circulating levels of 103 immunological proteins and 7 steroid hormones. We also investigated the correlation of the most interesting SNPs with cytokine levels after in vitro stimulation of whole blood, peripheral mononuclear cells (PBMCs), and monocyte-derived macrophages with LPS, PHA, Pam3Cys, and Staphylococcus Aureus. The meta-analysis of our data with those from six large cohorts confirmed that each copy of the FTOrs9939609A, HNF1Brs7501939T, HNF1Brs757210T, HNF1Brs4430796G, and JAZF1rs10486567A alleles significantly decreased risk of developing PCa (p = 3.70 × 10-5, p = 9.39 × 10-54, p = 5.04 × 10-54, p = 1.19 × 10-71, and p = 1.66 × 10-18, respectively). Although it was not statistically significant after correction for multiple testing, we also found that the NOTCH2rs10923931T and RBMS1rs7593730 SNPs associated with the risk of developing PCa (p = 8.49 × 10-4 and 0.004). Interestingly, we found that the protective effect attributed to the HFN1B locus could be mediated by the SULT1A1 protein (p = 0.00030), an arylsulfotransferase that catalyzes the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds. In addition to these results, eQTL analysis revealed that the HNF1Brs7501939, HNF1Brs757210, HNF1Brs4430796, NOTCH2rs10923931, and RBMS1rs7593730 SNPs influence the risk of PCa through the modulation of mRNA levels of their respective genes in whole blood and/or liver. These results confirm that functional TD2-related variants influence the risk of developing PCa, but also highlight the need of additional experiments to validate our functional results in a tumoral tissue context.
Collapse
Affiliation(s)
- José Manuel Sánchez-Maldonado
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
- Hematology Department, Virgen de las Nieves University Hospital, 18012 Granada, Spain;
- Instituto de Investigación Biosanataria IBs. Granada, 18012 Granada, Spain
| | - Ricardo Collado
- Medical Oncology Department, Hospital de San Pedro Alcántara, 10003 Cáceres, Spain; (R.C.); (M.I.B.-F.); (J.O.-R.)
| | - Antonio José Cabrera-Serrano
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
- Hematology Department, Virgen de las Nieves University Hospital, 18012 Granada, Spain;
- Instituto de Investigación Biosanataria IBs. Granada, 18012 Granada, Spain
| | - Rob Ter Horst
- Department of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, The Netherlands; (R.T.H.); (Y.L.); (M.G.N.)
| | - Fernando Gálvez-Montosa
- Department of Medical Oncology, Complejo Hospitalario de Jaén, 23007 Jaén, Spain; (F.G.-M.); (F.J.G.-V.); (J.A.L.L.); (P.S.-R.)
| | - Inmaculada Robles-Fernández
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
| | - Verónica Arenas-Rodríguez
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
- Department of Biochemistry and Molecular Biology III, Faculty of Medicine, University of Granada, 18016 Granada, Spain;
| | - Blanca Cano-Gutiérrez
- Department of Biochemistry and Molecular Biology III, Faculty of Medicine, University of Granada, 18016 Granada, Spain;
| | - Olivier Bakker
- Department of Genetics, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands;
| | | | - Francisco José García-Verdejo
- Department of Medical Oncology, Complejo Hospitalario de Jaén, 23007 Jaén, Spain; (F.G.-M.); (F.J.G.-V.); (J.A.L.L.); (P.S.-R.)
| | - José Antonio López López
- Department of Medical Oncology, Complejo Hospitalario de Jaén, 23007 Jaén, Spain; (F.G.-M.); (F.J.G.-V.); (J.A.L.L.); (P.S.-R.)
| | - Jesús Olivares-Ruiz
- Medical Oncology Department, Hospital de San Pedro Alcántara, 10003 Cáceres, Spain; (R.C.); (M.I.B.-F.); (J.O.-R.)
| | | | | | | | - Yang Li
- Department of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, The Netherlands; (R.T.H.); (Y.L.); (M.G.N.)
- Centre for Individualised Infection Medicine (CiiM) & TWINCORE, Joint Ventures between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), 30625 Hannover, Germany
| | - Mihai G. Netea
- Department of Internal Medicine and Radboud Centre for Infectious Diseases, Radboud University Nijmegen Medical Center, 6525 GA Nijmegen, The Netherlands; (R.T.H.); (Y.L.); (M.G.N.)
- Department for Immunology & Metabolism, Life and Medical Sciences Institute (LIMES), University of Bonn, 53115 Bonn, Germany
| | - Manuel Jurado
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
- Hematology Department, Virgen de las Nieves University Hospital, 18012 Granada, Spain;
- Instituto de Investigación Biosanataria IBs. Granada, 18012 Granada, Spain
- Department of Medicine, Faculty of Medicine, University of Granada, 18016 Granada, Spain
| | - Jose Antonio Lorente
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
- Department of Legal Medicine, Faculty of Medicine, University of Granada, 18016 Granada, Spain
| | - Pedro Sánchez-Rovira
- Department of Medical Oncology, Complejo Hospitalario de Jaén, 23007 Jaén, Spain; (F.G.-M.); (F.J.G.-V.); (J.A.L.L.); (P.S.-R.)
| | - María Jesús Álvarez-Cubero
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
- Department of Biochemistry and Molecular Biology III, Faculty of Medicine, University of Granada, 18016 Granada, Spain;
| | - Juan Sainz
- Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, 18016 Granada, Spain; (J.M.S.-M.); (A.J.C.-S.); (I.R.-F.); (V.A.-R.); (M.J.); (J.A.L.); (M.J.Á.-C.)
- Hematology Department, Virgen de las Nieves University Hospital, 18012 Granada, Spain;
- Instituto de Investigación Biosanataria IBs. Granada, 18012 Granada, Spain
- Department of Biochemistry and Molecular Biology I, Faculty of Sciences, University of Granada, 18071 Granada, Spain
- Correspondence: ; Tel.: +34-95871-5500 (ext. 126); Fax: +34-9-5863-7071
| |
Collapse
|
9
|
Ofori JK, Karagiannopoulos A, Nagao M, Westholm E, Ramadan S, Wendt A, Esguerra JL, Eliasson L. Human Islet MicroRNA-200c Is Elevated in Type 2 Diabetes and Targets the Transcription Factor ETV5 to Reduce Insulin Secretion. Diabetes 2022; 71:275-284. [PMID: 34753799 PMCID: PMC8914283 DOI: 10.2337/db21-0077] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 10/29/2021] [Indexed: 11/13/2022]
Abstract
MicroRNAs (miRNAs) are part of deregulated insulin secretion in type 2 diabetes (T2D) development. Rodent models have suggested miR-200c to be involved, but the role and potential as therapeutic target of this miRNA in human islets are not clear. Here we report increased expression of miR-200c in islets from T2D as compared with nondiabetic (ND) donors and display results showing reduced glucose-stimulated insulin secretion in EndoC-βH1 cells overexpressing miR-200c. We identify transcription factor ETV5 as the top rank target of miR-200c in human islets using TargetScan in combination with Pearson correlation analysis of miR-200c and mRNA expression data from the same human donors. Among other targets were JAZF1, as earlier shown in miR-200 knockout mice. Accordingly, linear model analysis of ETV5 and JAZF1 gene expression showed reduced expression of both genes in islets from human T2D donors. Western blot analysis confirmed the reduced expression of ETV5 on the protein level in EndoC-βH1 cells overexpressing miR-200c, and luciferase assay validated ETV5 as a direct target of miR-200c. Finally, LNA knockdown of miR-200c increased glucose-stimulated insulin secretion in islets from T2D donors approximately threefold. Our data reveal a vital role of the miR-200c-ETV5 axis in β-cell dysfunction and pathophysiology of T2D.
Collapse
|
10
|
Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach. Pharmaceutics 2022; 14:pharmaceutics14020234. [PMID: 35213968 PMCID: PMC8878225 DOI: 10.3390/pharmaceutics14020234] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 01/08/2022] [Accepted: 01/14/2022] [Indexed: 12/15/2022] Open
Abstract
Identification of the correct targets is a key element for successful drug development. However, there are limited approaches for predicting drug targets for specific diseases using omics data, and few have leveraged expression profiles from gene perturbations. We present a novel computational approach for drug target discovery based on machine learning (ML) models. ML models are first trained on drug-induced expression profiles with outcomes defined as whether the drug treats the studied disease. The goal is to “learn” the expression patterns associated with treatment. Then, the fitted ML models were applied to expression profiles from gene perturbations (overexpression (OE)/knockdown (KD)). We prioritized targets based on predicted probabilities from the ML model, which reflects treatment potential. The methodology was applied to predict targets for hypertension, diabetes mellitus (DM), rheumatoid arthritis (RA), and schizophrenia (SCZ). We validated our approach by evaluating whether the identified targets may ‘re-discover’ known drug targets from an external database (OpenTargets). Indeed, we found evidence of significant enrichment across all diseases under study. A further literature search revealed that many candidates were supported by previous studies. For example, we predicted PSMB8 inhibition to be associated with the treatment of RA, which was supported by a study showing that PSMB8 inhibitors (PR-957) ameliorated experimental RA in mice. In conclusion, we propose a new ML approach to integrate the expression profiles from drugs and gene perturbations and validated the framework. Our approach is flexible and may provide an independent source of information when prioritizing drug targets.
Collapse
|
11
|
Ding Q, Zhao W, Long J, Alsafar H, Zhou Q, Chen H. Cis-regulation of antisense noncoding RNA at the JAZF1 locus in type 2 diabetes. J Gene Med 2022; 24:e3407. [PMID: 34978128 DOI: 10.1002/jgm.3407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 11/25/2021] [Accepted: 12/16/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Several genomic loci of type 2 diabetes (T2D) nominated in genome-wide association studies (GWASs) have been suggested to regulate metabolism in muscle. However, a large portion of the genetic risk and the underlying regulation remain unexplained. This study aimed to localize the potentially functional regions or genes at juxtaposed with another zinc finger protein 1 (JAZF1) locus and interpret their possible biological mechanisms in the muscle of T2D. METHODS AND RESULTS With a cross-population meta-analysis of 7 GWASs, we identified a linkage disequilibrium (LD) block within intron 1 of JAZF1 that was significantly associated with T2D (FDR < 0.05). The colocalization analysis showed a significant association between genetically determined expression of JAZF1 in skeletal muscle and T2D with a strong probability of colocalization (PP4=75.09%). This region also encodes the upstream regulatory region (URR) of the antisense noncoding RNA JAZF1-AS1. Expression-QTL (e-QTL) analysis detected a regulatory SNP within this LD block, rs864745, that is associated with the expression of JAZF1-AS1 and JAZF1. With in vitro cloning, we further reported the role of JAZF1-AS1 in cis-regulating JAZF1 by directly forming RNA double strands. Downregulation of JAZF1, caused by JAZF1-AS1 depletion, inhibited the glucose uptake and lipid oxidation in skeletal muscle. CONCLUSIONS This study proposes a strategy to identify a novel T2D gene at the reported locus and generated a model in which polymorphisms at JAZF1 influence T2D risk through antisense-mediated gene regulation.
Collapse
Affiliation(s)
- Qiuju Ding
- Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Weiwei Zhao
- Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Jirong Long
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America
| | - Habiba Alsafar
- Center for Biotechnology, Khalifa University of Science & Technology, Abu Dhabi, United Arab Emirates
| | - Qing Zhou
- Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| | - Huimei Chen
- Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
| |
Collapse
|
12
|
Dai H, Qian Y, Lv H, Jiang L, Jiang H, Shen M, Chen H, Chen Y, Zheng S, Fu Q, Yang T, Xu K. Rs864745 in JAZF1, an Islet Function Associated Variant, Correlates With Plasma Lipid Levels in Both Type 1 and Type 2 Diabetes Status, but Not Healthy Subjects. Front Endocrinol (Lausanne) 2022; 13:898893. [PMID: 35846288 PMCID: PMC9283698 DOI: 10.3389/fendo.2022.898893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2022] [Accepted: 05/31/2022] [Indexed: 11/29/2022] Open
Abstract
OBJECTIVE This study aims to reveal the association between JAZF1 rs864745 A>G variant and type 2 diabetes (T2D), type 1 diabetes (T1D) risk, and their correlation with clinical features, including islet function, islet autoimmunity, and plasma lipid levels. METHODS We included 2505 healthy controls based on oral glucose tolerance test (OGTT), 1736 unrelated T2D, and 1003 unrelated autoantibody-positive T1D individuals. Binary logistic regression was performed to evaluate the relationships between rs864745 in JAZF1 and T2D, T1D, and islet-specific autoantibody status under the additive model, while multiple linear regression was used to assess its effect on glycemic-related quantitative traits and plasma lipid levels. RESULTS We did not find any association between rs864745 in JAZF1 and T2D, T1D, or their subgroups (All P > 0.05). For glycemic traits, we found that the G allele of this variant was significantly associated with higher 120 min insulin level, insulinogenic index (IGI), corrected insulin response (CIR), and acute insulin response (BIGTT-AIR) (P = 0.033, 0.006, 0.009, and 0.016, respectively) in healthy individuals. Similar associations were observed in newly diagnosed T2D but not T1D individuals. Although this variant had no impact on islet autoimmunity (All P > 0.05), significant associations with plasma total cholesterol (TC) and low-density lipoprotein (LDL) level stratified by JAZF1 rs864745 variant were observed in the disease status of T2D (P = 0.002 and 0.003) and T1D (P = 0.024 and 0.009), with significant heterogeneity to healthy individuals. CONCLUSIONS The common JAZF1 rs864745 variant contributes to islet function and lipid metabolism, which might be put into genetic risk scores to assess the risk of related clinical features.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Tao Yang
- *Correspondence: Tao Yang, ; Kuanfeng Xu,
| | | |
Collapse
|
13
|
Analysis of the Potential Genetic Links between Psoriasis and Cardiovascular Risk Factors. Int J Mol Sci 2021; 22:ijms22169063. [PMID: 34445769 PMCID: PMC8396451 DOI: 10.3390/ijms22169063] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 08/20/2021] [Accepted: 08/21/2021] [Indexed: 01/07/2023] Open
Abstract
Cardiovascular risk factors are one of the most common comorbidities in psoriasis. A higher prevalence of hypertension, insulin resistance and type 2 diabetes, dyslipidemia, obesity, metabolic syndrome, depression, as well as cardiovascular disease was confirmed in psoriatic patients in comparison to the general population. Data suggest that psoriasis and systemic inflammatory disorders may originate from the pleiotropic interactions with many genetic pathways. In this review, the authors present the current state of knowledge on the potential genetic links between psoriasis and cardiovascular risk factors. The understanding of the processes linking psoriasis with cardiovascular risk factors can lead to improvement of psoriasis management in the future.
Collapse
|
14
|
Jeong J, Jang S, Park S, Kwon W, Kim SY, Jang S, Ko J, Park SJ, Lim SG, Yoon D, Yi J, Lee S, Kim MO, Choi SK, Ryoo ZY. JAZF1 heterozygous knockout mice show altered adipose development and metabolism. Cell Biosci 2021; 11:161. [PMID: 34407873 PMCID: PMC8375039 DOI: 10.1186/s13578-021-00625-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 06/10/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Juxtaposed with another zinc finger protein 1 (JAZF1) is associated with metabolic disorders, including type 2 diabetes mellitus (T2DM). Several studies showed that JAZF1 and body fat mass are closely related. We attempted to elucidate the JAZF1 functions on adipose development and related metabolism using in vitro and in vivo models. RESULTS The JAZF1 expression was precisely regulated during adipocyte differentiation of 3T3-L1 preadipocyte and mouse embryonic fibroblasts (MEFs). Homozygous JAZF1 deletion (JAZF1-KO) resulted in impaired adipocyte differentiation in MEF. The JAZF1 role in adipocyte differentiation was demonstrated by the regulation of PPARγ-a key regulator of adipocyte differentiation. Heterozygous JAZF1 deletion (JAZF1-Het) mice fed a normal diet (ND) or a high-fat diet (HFD) had less adipose tissue mass and impaired glucose homeostasis than the control (JAZF1-Cont) mice. However, other metabolic organs, such as brown adipose tissue and liver, were negligible effect on JAZF1 deficiency. CONCLUSION Our findings emphasized the JAZF1 role in adipocyte differentiation and related metabolism through the heterozygous knockout mice. This study provides new insights into the JAZF1 function in adipose development and metabolism, informing strategies for treating obesity and related metabolic disorders.
Collapse
Affiliation(s)
- Jain Jeong
- Digestive Diseases Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
| | - Soyoung Jang
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea
| | - Song Park
- Core Protein Resources Center, DGIST, Daegu, 42988, Republic of Korea.,Department of Brain and Cognitive Sciences, DGIST, Daegu, Republic of Korea
| | - Wookbong Kwon
- Division of Biotechnology, DGIST, Daegu, Republic of Korea
| | - Si-Yong Kim
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea
| | - Soyoen Jang
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea
| | - Jiwon Ko
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea
| | - Si Jun Park
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea
| | - Su-Geun Lim
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea
| | - Duhak Yoon
- Department of Animal Science, Kyungpook National University, Daegu, 37224, Republic of Korea
| | - Junkoo Yi
- Gyeongsangbukdo Livestock Research Institute, Yeongju, Republic of Korea
| | - Sanggyu Lee
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea
| | - Myoung Ok Kim
- School of Animal Science and Biotechnology, Kyungpook National University, Daegu, Korea
| | - Seong-Kyoon Choi
- Core Protein Resources Center, DGIST, Daegu, 42988, Republic of Korea. .,Division of Biotechnology, DGIST, Daegu, Republic of Korea.
| | - Zae Young Ryoo
- School of Life Sciences, BK21 FOUR KNU Creative BioResearch, Kyungpook National University, Daegu, 41566, Republic of Korea.
| |
Collapse
|
15
|
Ustianowski P, Malinowski D, Kopytko P, Czerewaty M, Tarnowski M, Dziedziejko V, Safranow K, Pawlik A. ADCY5, CAPN10 and JAZF1 Gene Polymorphisms and Placental Expression in Women with Gestational Diabetes. Life (Basel) 2021; 11:life11080806. [PMID: 34440550 PMCID: PMC8399092 DOI: 10.3390/life11080806] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 08/06/2021] [Accepted: 08/07/2021] [Indexed: 12/12/2022] Open
Abstract
Gestational diabetes mellitus (GDM) is carbohydrate intolerance that occurs during pregnancy. This disease may lead to various maternal and neonatal complications; therefore, early diagnosis is very important. Because of the similarity in pathogenesis of type 2 diabetes and GDM, the genetic variants associated with type 2 diabetes are commonly investigated in GDM. The aim of the present study was to examine the associations between the polymorphisms in the ADCY5 (rs11708067, rs2877716), CAPN10 (rs2975760, rs3792267), and JAZF1 (rs864745) genes and GDM as well as to determine the expression of these genes in the placenta. This study included 272 pregnant women with GDM and 348 pregnant women with normal glucose tolerance. The diagnosis of GDM was based on a 75 g oral glucose tolerance test (OGTT) at 24–28 weeks gestation, according to International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria. There were no statistically significant differences in the distribution of the ADCY5 gene (rs11708067, rs2877716) and CAPN10 gene (rs2975760, rs3792267) polymorphisms between pregnant women with normal carbohydrate tolerance and pregnant women with GDM. We have shown a lower frequency of JAZF1 gene rs864745 C allele carriers among women with GDM CC + CT vs. TT (OR = 0.60, 95% CI = 0.41–0.87, p = 0.006), and C vs. T (OR = 0.75, 95% CI = 0.60–0.95, p = 0.014). In addition, ADCY5 and JAZF1 gene expression was statistically significantly increased in the placentas of women with GDM compared with that of healthy women. The expression of the CAPN10 gene did not differ significantly between women with and without GDM. Our results indicate increased expression of JAZF1 and ADCY5 genes in the placentas of women with GDM as well as a protective effect of the C allele of the JAZF1 rs864745 gene polymorphism on the development of GDM in pregnant women.
Collapse
Affiliation(s)
- Przemysław Ustianowski
- Department of Obstetrics and Gynecology, Pomeranian Medical University, 70-111 Szczecin, Poland;
| | - Damian Malinowski
- Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, 70-111 Szczecin, Poland;
| | - Patrycja Kopytko
- Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland; (P.K.); (M.C.); (M.T.)
| | - Michał Czerewaty
- Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland; (P.K.); (M.C.); (M.T.)
| | - Maciej Tarnowski
- Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland; (P.K.); (M.C.); (M.T.)
| | - Violetta Dziedziejko
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland; (V.D.); (K.S.)
| | - Krzysztof Safranow
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, 70-111 Szczecin, Poland; (V.D.); (K.S.)
| | - Andrzej Pawlik
- Department of Physiology, Pomeranian Medical University, 70-111 Szczecin, Poland; (P.K.); (M.C.); (M.T.)
- Correspondence:
| |
Collapse
|
16
|
Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells. Nat Commun 2021; 12:3133. [PMID: 34035238 PMCID: PMC8149827 DOI: 10.1038/s41467-021-22843-4] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Accepted: 04/04/2021] [Indexed: 12/13/2022] Open
Abstract
Heterozygous HNF1A gene mutations can cause maturity onset diabetes of the young 3 (MODY3), characterized by insulin secretion defects. However, specific mechanisms of MODY3 in humans remain unclear due to lack of access to diseased human pancreatic cells. Here, we utilize MODY3 patient-derived human induced pluripotent stem cells (hiPSCs) to study the effect(s) of a causal HNF1A+/H126D mutation on pancreatic function. Molecular dynamics simulations predict that the H126D mutation could compromise DNA binding and gene target transcription. Genome-wide RNA-Seq and ChIP-Seq analyses on MODY3 hiPSC-derived endocrine progenitors reveal numerous HNF1A gene targets affected by the mutation. We find decreased glucose transporter GLUT2 expression, which is associated with reduced glucose uptake and ATP production in the MODY3 hiPSC-derived β-like cells. Overall, our findings reveal the importance of HNF1A in regulating GLUT2 and several genes involved in insulin secretion that can account for the insulin secretory defect clinically observed in MODY3 patients. Heterozygous HNF1A mutations can give rise to maturity onset diabetes of the young 3 (MODY3), characterized by insulin secretion defects. Here the authors show that MODY3-related HNF1A mutation in patient hiPSCderived pancreatic cells decreases glucose transporter GLUT2 expression due to compromised DNA binding.
Collapse
|
17
|
Kobiita A, Godbersen S, Araldi E, Ghoshdastider U, Schmid MW, Spinas G, Moch H, Stoffel M. The Diabetes Gene JAZF1 Is Essential for the Homeostatic Control of Ribosome Biogenesis and Function in Metabolic Stress. Cell Rep 2021; 32:107846. [PMID: 32640216 DOI: 10.1016/j.celrep.2020.107846] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 04/23/2020] [Accepted: 06/11/2020] [Indexed: 02/07/2023] Open
Abstract
The ability of pancreatic β-cells to respond to increased demands for insulin during metabolic stress critically depends on proper ribosome homeostasis and function. Excessive and long-lasting stimulation of insulin secretion can elicit endoplasmic reticulum (ER) stress, unfolded protein response, and β-cell apoptosis. Here we show that the diabetes susceptibility gene JAZF1 is a key transcriptional regulator of ribosome biogenesis, global protein, and insulin translation. JAZF1 is excluded from the nucleus, and its expression levels are reduced upon metabolic stress and in diabetes. Genetic deletion of Jazf1 results in global impairment of protein synthesis that is mediated by defects in ribosomal protein synthesis, ribosomal RNA processing, and aminoacyl-synthetase expression, thereby inducing ER stress and increasing β-cell susceptibility to apoptosis. Importantly, JAZF1 function and its pleiotropic actions are impaired in islets of murine T2D and in human islets exposed to metabolic stress. Our study identifies JAZF1 as a central mediator of metabolic stress in β-cells.
Collapse
Affiliation(s)
- Ahmad Kobiita
- Institute of Molecular Health Sciences, ETH Zurich, Otto-Stern-Weg 7, HPL H36, 8093 Zürich, Switzerland
| | - Svenja Godbersen
- Institute of Molecular Health Sciences, ETH Zurich, Otto-Stern-Weg 7, HPL H36, 8093 Zürich, Switzerland
| | - Elisa Araldi
- Institute of Molecular Health Sciences, ETH Zurich, Otto-Stern-Weg 7, HPL H36, 8093 Zürich, Switzerland
| | - Umesh Ghoshdastider
- Institute of Molecular Health Sciences, ETH Zurich, Otto-Stern-Weg 7, HPL H36, 8093 Zürich, Switzerland
| | - Marc W Schmid
- MWSchmid GmbH, Möhrlistrasse 25, 8006 Zurich, Switzerland
| | - Giatgen Spinas
- Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitäts-Spital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland
| | - Holger Moch
- Department of Pathology and Molecular Pathology, University and University Hospital Zürich, Schmelzbergstrasse 12, 8091 Zürich, Switzerland
| | - Markus Stoffel
- Institute of Molecular Health Sciences, ETH Zurich, Otto-Stern-Weg 7, HPL H36, 8093 Zürich, Switzerland; Medical Faculty, University of Zurich, Zurich, Switzerland.
| |
Collapse
|
18
|
A Replication Study Identified Seven SNPs Associated with Quantitative Traits of Type 2 Diabetes among Chinese Population in A Cross-Sectional Study. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2020; 17:ijerph17072439. [PMID: 32260174 PMCID: PMC7177704 DOI: 10.3390/ijerph17072439] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/27/2020] [Revised: 03/31/2020] [Accepted: 04/01/2020] [Indexed: 12/17/2022]
Abstract
Genome-wide association studies (GWAS) have identified common variants for quantitative traits (insulin resistance and impaired insulin release) of type 2 diabetes (T2D) across different ethnics including China, but results were inconsistent. The study included 1654 subjects who were selected from the 2010–2012 China National Nutrition and Health Surveillance (CNNHS). Insulin resistance and impaired insulin release were assessed by homeostasis model assessment (HOMA). The study included 64 diabetes-related single nucleotide polymorphisms (SNPs), which were done using Mass ARRAY. A logistic regression model was employed to explore the associations of SNPs with insulin resistance and impaired insulin release by correcting for the confounders. The 5q11.2-rs4432842, RASGRP1-rs7403531, and SEC16B-rs574367 increased the risk of insulin resistance with OR = 1.23 (95% CI: 1.04–1.45, OR = 1.35 (95% CI: 1.13–1.62), OR = 1.34 (95% CI: 1.07–1.67), respectively, while MAEA-rs6815464 decreased the risk of insulin resistance (OR = 0.84, 95% CI: 0.71–1.00). CENTD2-rs1552224, TSPAN8-rs7961581 and ANK1-rs516946 was associated with increased risk of impaired insulin release with OR = 1.47 (95% CI: 1.09–1.99), OR = 1.25 (95% CI: 1.03–1.51), OR = 1.39 (95% CI: 1.07–1.81), respectively. Our findings would provide insight into the pathogenesis of individual SNPs and T2D.
Collapse
|
19
|
Hall E, Jönsson J, Ofori JK, Volkov P, Perfilyev A, Dekker Nitert M, Eliasson L, Ling C, Bacos K. Glucolipotoxicity Alters Insulin Secretion via Epigenetic Changes in Human Islets. Diabetes 2019; 68:1965-1974. [PMID: 31420409 DOI: 10.2337/db18-0900] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2018] [Accepted: 07/24/2019] [Indexed: 11/13/2022]
Abstract
Type 2 diabetes (T2D) is characterized by insufficient insulin secretion and elevated glucose levels, often in combination with high levels of circulating fatty acids. Long-term exposure to high levels of glucose or fatty acids impair insulin secretion in pancreatic islets, which could partly be due to epigenetic alterations. We studied the effects of high concentrations of glucose and palmitate combined for 48 h (glucolipotoxicity) on the transcriptome, the epigenome, and cell function in human islets. Glucolipotoxicity impaired insulin secretion, increased apoptosis, and significantly (false discovery rate <5%) altered the expression of 1,855 genes, including 35 genes previously implicated in T2D by genome-wide association studies (e.g., TCF7L2 and CDKN2B). Additionally, metabolic pathways were enriched for downregulated genes. Of the differentially expressed genes, 1,469 also exhibited altered DNA methylation (e.g., CDK1, FICD, TPX2, and TYMS). A luciferase assay showed that increased methylation of CDK1 directly reduces its transcription in pancreatic β-cells, supporting the idea that DNA methylation underlies altered expression after glucolipotoxicity. Follow-up experiments in clonal β-cells showed that knockdown of FICD and TPX2 alters insulin secretion. Together, our novel data demonstrate that glucolipotoxicity changes the epigenome in human islets, thereby altering gene expression and possibly exacerbating the secretory defect in T2D.
Collapse
Affiliation(s)
- Elin Hall
- Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Josefine Jönsson
- Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Jones K Ofori
- Islet Cell Exocytosis Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Petr Volkov
- Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Alexander Perfilyev
- Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Marloes Dekker Nitert
- Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Lena Eliasson
- Islet Cell Exocytosis Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Charlotte Ling
- Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| | - Karl Bacos
- Epigenetics and Diabetes Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Scania University Hospital, Malmö, Sweden
| |
Collapse
|
20
|
Liao ZZ, Wang YD, Qi XY, Xiao XH. JAZF1, a relevant metabolic regulator in type 2 diabetes. Diabetes Metab Res Rev 2019; 35:e3148. [PMID: 30838734 DOI: 10.1002/dmrr.3148] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Revised: 01/26/2019] [Accepted: 03/03/2019] [Indexed: 12/14/2022]
Abstract
Excessive adiposity and metabolic inflammation are the key risk factors of type 2 diabetes mellitus (T2DM). Juxtaposed with another zinc finger gene 1 (JAZF1) has been identified as a novel transcriptional cofactor, with function of regulating glucose and lipid homeostasis and inflammation. JAZF1 is involved in metabolic process of T2DM via interaction with several nuclear receptors and protein kinases. Additionally, increasing evidence from genome-wide association studies (GWAS) has shown that JAZF1 polymorphisms are closely associated with T2DM. In this review, we have updated the latest research advances on JAZF1 and discussed its regulatory network in T2DM. The association between JAZF1 polymorphisms and T2DM is discussed as well. The information provided is of importance for guiding future studies as well as for the design of JAZF1-based T2DM therapy.
Collapse
Affiliation(s)
- Zhe-Zhen Liao
- Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, China
| | - Ya-Di Wang
- Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, China
| | - Xiao-Yan Qi
- Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, China
| | - Xin-Hua Xiao
- Department of Metabolism and Endocrinology, The First Affiliated Hospital of University of South China, Hengyang, China
| |
Collapse
|
21
|
Ahbara A, Bahbahani H, Almathen F, Al Abri M, Agoub MO, Abeba A, Kebede A, Musa HH, Mastrangelo S, Pilla F, Ciani E, Hanotte O, Mwacharo JM. Genome-Wide Variation, Candidate Regions and Genes Associated With Fat Deposition and Tail Morphology in Ethiopian Indigenous Sheep. Front Genet 2019; 9:699. [PMID: 30687385 PMCID: PMC6334744 DOI: 10.3389/fgene.2018.00699] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2018] [Accepted: 12/13/2018] [Indexed: 12/03/2022] Open
Abstract
Variations in body weight and in the distribution of body fat are associated with feed availability, thermoregulation, and energy reserve. Ethiopia is characterized by distinct agro-ecological and human ethnic farmer diversity of ancient origin, which have impacted on the variation of its indigenous livestock. Here, we investigate autosomal genome-wide profiles of 11 Ethiopian indigenous sheep populations using the Illumina Ovine 50 K SNP BeadChip assay. Sheep from the Caribbean, Europe, Middle East, China, and western, northern and southern Africa were included to address globally, the genetic variation and history of Ethiopian populations. Population relationship and structure analysis separated Ethiopian indigenous fat-tail sheep from their North African and Middle Eastern counterparts. It indicates two main genetic backgrounds and supports two distinct genetic histories for African fat-tail sheep. Within Ethiopian sheep, our results show that the short fat-tail sheep do not represent a monophyletic group. Four genetic backgrounds are present in Ethiopian indigenous sheep but at different proportions among the fat-rump and the long fat-tail sheep from western and southern Ethiopia. The Ethiopian fat-rump sheep share a genetic background with Sudanese thin-tail sheep. Genome-wide selection signature analysis identified eight putative candidate regions spanning genes influencing growth traits and fat deposition (NPR2, HINT2, SPAG8, INSR), development of limbs and skeleton, and tail formation (ALX4, HOXB13, BMP4), embryonic development of tendons, bones and cartilages (EYA2, SULF2), regulation of body temperature (TRPM8), body weight and height variation (DIS3L2), control of lipogenesis and intracellular transport of long-chain fatty acids (FABP3), the occurrence and morphology of horns (RXFP2), and response to heat stress (DNAJC18). Our findings suggest that Ethiopian fat-tail sheep represent a uniquely admixed but distinct genepool that presents an important resource for understanding the genetic control of skeletal growth, fat metabolism and associated physiological processes.
Collapse
Affiliation(s)
- Abulgasim Ahbara
- School of Life Sciences, University of Nottingham, Nottingham, United Kingdom
- Department of Zoology, Faculty of Sciences, Misurata University, Misurata, Libya
| | - Hussain Bahbahani
- Department of Biological Sciences, Faculty of Science, Kuwait University, Safat, Kuwait
| | - Faisal Almathen
- Department of Veterinary Public Health and Animal Husbandry, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
| | - Mohammed Al Abri
- Department of Animal and Veterinary Sciences, College of Agriculture and Marine Sciences, Sultan Qaboos University, Muscat, Oman
| | | | - Ayelle Abeba
- Debre Berhan Research Centre, Debre Berhan, Ethiopia
| | - Adebabay Kebede
- Amhara Regional Agricultural Research Institute, Bahir Dar, Ethiopia
- LiveGene, International Livestock Research Institute, Addis Ababa, Ethiopia
| | - Hassan Hussein Musa
- Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan
| | - Salvatore Mastrangelo
- Dipartimento di Scienze Agrarie e Forestali, Viale delle Scienze, Università Palermo, Palermo, Italy
| | - Fabio Pilla
- Dipartimento Agricoltura, Ambiente e Alimenti, Università degli Studi del Molise, Campobasso, Italy
| | - Elena Ciani
- Dipartimento di Bioscienze, Biotecnologie e Biofarmaceutica, Università degli Studi di Bari “Aldo Moro ”, Bari, Italy
| | - Olivier Hanotte
- School of Life Sciences, University of Nottingham, Nottingham, United Kingdom
- LiveGene, International Livestock Research Institute, Addis Ababa, Ethiopia
| | - Joram M. Mwacharo
- Small Ruminant Genomics, International Center for Agricultural Research in the Dry Areas (ICARDA), Addis Ababa, Ethiopia
| |
Collapse
|
22
|
Dong Y, Teleman AA, Jedmowski C, Wirtz M, Hell R. The Arabidopsis THADA homologue modulates TOR activity and cold acclimation. PLANT BIOLOGY (STUTTGART, GERMANY) 2019; 21 Suppl 1:77-83. [PMID: 30098100 DOI: 10.1111/plb.12893] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 08/02/2018] [Indexed: 05/21/2023]
Abstract
Low temperature is one of the most important environmental factors that affect global survival of humans and animals and equally importantly the distribution of plants and crop productivity. Survival of metazoan cells under cold stress requires regulation of the sensor-kinase Target Of Rapamycin (TOR). TOR controls growth of eukaryotic cells by adjusting anabolic and catabolic metabolism. Previous studies identified the Thyroid Adenoma Associated (THADA) gene as the major effect locus by positive selection in the evolution of modern human adapted to cold. Here we investigate the role of THADA in TOR signaling and cold acclimation of plants. We applied BLAST searches and homology modeling to identify the AtTHADA (AT3G55160) in Arabidopsis thaliana as the highly probable orthologue protein. Reverse genetics approaches were combined with immunological detection of TOR activity and metabolite profiling to address the role of the TOR and THADA for growth regulation and cold acclimation. Depletion of the AtTHADA gene caused complete or partial loss of full-length mRNA, respectively, and significant retardation of growth under non-stressed conditions. Furthermore, depletion of AtTHADA caused hypersensitivity towards low-temperatures. Atthada displayed a lowered energy charge. This went along with decreased TOR activity, which offers a molecular explanation for the slow growth phenotype of Atthada. Finally, we used TOR RNAi lines to identify the de-regulation of TOR activity as one determinant for sensitivity towards low-temperatures. Taken together our results provide evidence for a conserved function of THADA in cold acclimation of eukaryotes and suggest that cold acclimation in plants requires regulation of TOR.
Collapse
Affiliation(s)
- Y Dong
- Centre for Organismal Studies (COS), University of Heidelberg, Heidelberg, Germany
| | - A A Teleman
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - M Wirtz
- Centre for Organismal Studies (COS), University of Heidelberg, Heidelberg, Germany
| | - R Hell
- Centre for Organismal Studies (COS), University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
23
|
Mead TJ, Apte SS. ADAMTS proteins in human disorders. Matrix Biol 2018; 71-72:225-239. [PMID: 29885460 DOI: 10.1016/j.matbio.2018.06.002] [Citation(s) in RCA: 169] [Impact Index Per Article: 28.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 06/04/2018] [Accepted: 06/05/2018] [Indexed: 02/07/2023]
Abstract
ADAMTS proteins are a superfamily of 26 secreted molecules comprising two related, but distinct families. ADAMTS proteases are zinc metalloendopeptidases, most of whose substrates are extracellular matrix (ECM) components, whereas ADAMTS-like proteins lack a metalloprotease domain, reside in the ECM and have regulatory roles vis-à-vis ECM assembly and/or ADAMTS activity. Evolutionary conservation and expansion of ADAMTS proteins in mammals is suggestive of crucial embryologic or physiological roles in humans. Indeed, Mendelian disorders or birth defects resulting from naturally occurring ADAMTS2, ADAMTS3, ADAMTS10, ADAMTS13, ADAMTS17, ADAMTS20, ADAMTSL2 and ADAMTSL4 mutations as well as numerous phenotypes identified in genetically engineered mice have revealed ADAMTS participation in major biological pathways. Important roles have been identified in a few acquired conditions. ADAMTS5 is unequivocally implicated in pathogenesis of osteoarthritis via degradation of aggrecan, a major structural proteoglycan in cartilage. ADAMTS7 is strongly associated with coronary artery disease and promotes atherosclerosis. Autoantibodies to ADAMTS13 lead to a platelet coagulopathy, thrombotic thrombocytopenic purpura, which is similar to that resulting from ADAMTS13 mutations. ADAMTS proteins have numerous potential connections to other human disorders that were identified by genome-wide association studies. Here, we review inherited and acquired human disorders in which ADAMTS proteins participate, and discuss progress and prospects in therapeutics.
Collapse
Affiliation(s)
- Timothy J Mead
- Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, United States
| | - Suneel S Apte
- Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, United States.
| |
Collapse
|
24
|
Sharaf SA, Kantoush NA, Ayoub DF, Ibrahim AA, Abdelaal AA, Aziz RA, ElHefnawi MM, Ahmed AN. Altered expression of WFS1 and NOTCH2 genes associated with diabetic nephropathy in T2DM patients. Diabetes Res Clin Pract 2018; 140:304-313. [PMID: 29626590 DOI: 10.1016/j.diabres.2018.03.053] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Revised: 03/18/2018] [Accepted: 03/29/2018] [Indexed: 12/13/2022]
Abstract
AIM The increased incidence of type 2 diabetes mellitus (T2DM) and the importance of early identification and management of its complications, especially diabetic nephropathy (DN), have spotted the light on genetic factors that increase risk of T2DM and its related nephropathy. The present study aimed at investigating expression of (KCNJ11, ABCC8, JAZF1, WFS1, PPARG, NOTCH2 and EXOSC4) genes in peripheral blood of T2DM patients. METHOD The study included 30 non-complicated T2DM patients, 30 patients with DN and 40 healthy controls. Quantitative Real Time PCR Array was used to study gene expression. RESULTS NOTCH2 showed higher expression while KCNJ11, JAZF1, WFS1 and PPARG genes showed lower expression in DN patients compared to non-complicated patients. KCNJ11, JAZF1, WFS1, PPARG, and EXOSC4 expression showed significant negative correlation with microalbumin, while NOTCH2 expression was significantly positively correlated with microalbumin. AS regard HbA1c and studied genes expression, there was significant negative correlation between WFS1 expression and HbA1c, while NOTCH2, KCNJ11, JAZF1, PPARG, EXOSC4 expression didn't show significant correlation with HbA1c. Risk ratio of studied genes expression showed that WFS1 and NOTCH2 had highest risk ratio (30) and highest sensitivity and specificity, in relation to DN and they were the best predictors in the group of studied genes at cut off value of ≤0.861 for WFS1 and ≥0.678 for NOTCH2. CONCLUSION Altered expression of WFS1 and NOTCH2 genes may play a role in pathogenesis and development of DN in patients with T2DM. These results may contribute in early identification and management of DN.
Collapse
Affiliation(s)
- Sahar A Sharaf
- Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Nagwa A Kantoush
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Dina F Ayoub
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Alshaymaa A Ibrahim
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt.
| | - Amaal A Abdelaal
- Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Rokaya Abdel Aziz
- Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
| | - Mahmoud M ElHefnawi
- Biomedical Informatics and Chemoinformatics Group, Informatics and Systems Department, Division of Engineering Research, National Research Centre, Cairo, Egypt
| | - Amira N Ahmed
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| |
Collapse
|
25
|
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis. Oncotarget 2018; 7:59029-59048. [PMID: 27437873 PMCID: PMC5312293 DOI: 10.18632/oncotarget.10665] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Accepted: 05/19/2016] [Indexed: 01/01/2023] Open
Abstract
Diabetogenic single nucleotide polymorphisms (SNPs) have recently been associated with multiple myeloma (MM) risk but their impact on overall survival (OS) of MM patients has not been analysed yet. In order to investigate the impact of 58 GWAS-identified variants for type 2 diabetes (T2D) on OS of patients with MM, we analysed genotyping data of 936 MM patients collected by the International Multiple Myeloma rESEarch (IMMENSE) consortium and an independent set of 700 MM patients recruited by the University Clinic of Heidelberg. A meta-analysis of the cox regression results of the two sets showed that rs7501939 located in the HNF1B gene negatively impacted OS (HRRec= 1.44, 95% CI = 1.18-1.76, P = 0.0001). The meta-analysis also showed a noteworthy gender-specific association of the SLC30A8rs13266634 SNP with OS. The presence of each additional copy of the minor allele at rs13266634 was associated with poor OS in men whereas no association was seen in women (HRMen-Add = 1.32, 95% CI 1.13-1.54, P = 0.0003). In conclusion, these data suggest that the HNF1Brs7501939 SNP confers poor OS in patients with MM and that a SNP in SLC30A8 affect OS in men.
Collapse
|
26
|
Schartner C, Scholz CJ, Weber H, Post A, Freudenberg F, Grünewald L, Reif A. The regulation of tetraspanin 8 gene expression-A potential new mechanism in the pathogenesis of bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2017; 174:740-750. [PMID: 28777493 DOI: 10.1002/ajmg.b.32571] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Accepted: 06/26/2017] [Indexed: 01/13/2023]
Abstract
In a previous study, we identified the single nucleotide polymorphism (SNP) rs4500567, located in the upstream region of tetraspanin 8 (TSPAN8), to be associated with bipolar disorder (BD). Due to its proximal position, the SNP might have an impact on promoter activity, thus on TSPAN8 gene expression. We investigated the impact of rs4500567 on TSPAN8 expression in vitro with luciferase-based promoter assays in human embryonic kidney (HEK293) and neuroblastoma cells (SH-SY5Y), and its effect on expression of downstream associated genes by microarray-based transcriptome analyses. Immunohistochemical localization studies on murine brain slices served to identify possible target regions of altered TSPAN8 expression in the brain. Promoter assays revealed decreased TSPAN8 expression in presence of the minor allele. Transcriptome analyses of TSPAN8-knockdown cells, mirroring the effects of putatively reduced TSPAN8 expression in minor allele carriers, resulted in 231 differentially expressed genes with enrichments of relevant signaling pathways for psychiatric disorders and neuronal development. Finally, we demonstrate Tspan8 abundance in mouse cerebellum and hippocampus. These findings point to a role of TSPAN8 in neuronal function or development. Considering a rather protective effect of the minor allele of rs4500567, our findings reveal a possible novel mechanism that contributes to the development of BD.
Collapse
Affiliation(s)
- Christoph Schartner
- Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Bavaria, Germany
| | | | - Heike Weber
- Department of Psychiatry, Psychosomatics and Psychotherapy, University of Wuerzburg, Wuerzburg, Bavaria, Germany.,Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Antonia Post
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Florian Freudenberg
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Lena Grünewald
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany
| | - Andreas Reif
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
27
|
Wang H, Wang Z, Rani PL, Fu X, Yu W, Bao F, Yu G, Li J, Li L, Sun L, Yue Z, Zhao Q, Pan Q, Cao J, Wang C, Chi X, Wang Y, Yang Q, Mi Z, Liu H, Zhang F. Identification of PTPN22
,ST6GAL1
and JAZF1
as psoriasis risk genes demonstrates shared pathogenesis between psoriasis and diabetes. Exp Dermatol 2017; 26:1112-1117. [DOI: 10.1111/exd.13393] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/18/2017] [Indexed: 01/02/2023]
|
28
|
Moraru A, Cakan-Akdogan G, Strassburger K, Males M, Mueller S, Jabs M, Muelleder M, Frejno M, Braeckman BP, Ralser M, Teleman AA. THADA Regulates the Organismal Balance between Energy Storage and Heat Production. Dev Cell 2017; 41:72-81.e6. [PMID: 28399403 PMCID: PMC5392496 DOI: 10.1016/j.devcel.2017.03.016] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Revised: 02/22/2017] [Accepted: 03/15/2017] [Indexed: 11/25/2022]
Abstract
Human susceptibility to obesity is mainly genetic, yet the underlying evolutionary drivers causing variation from person to person are not clear. One theory rationalizes that populations that have adapted to warmer climates have reduced their metabolic rates, thereby increasing their propensity to store energy. We uncover here the function of a gene that supports this theory. THADA is one of the genes most strongly selected during evolution as humans settled in different climates. We report here that THADA knockout flies are obese, hyperphagic, have reduced energy production, and are sensitive to the cold. THADA binds the sarco/ER Ca2+ ATPase (SERCA) and acts on it as an uncoupler. Reducing SERCA activity in THADA mutant flies rescues their obesity, pinpointing SERCA as a key effector of THADA function. In sum, this identifies THADA as a regulator of the balance between energy consumption and energy storage, which was selected during human evolution. Drosophila knockouts of the conserved gene THADA are obese and hyperphagic THADA knockouts produce less heat and are cold sensitive THADA binds SERCA and uncouples its ATP hydrolysis from Ca2+ pumping Reducing SERCA activity rescues the THADA loss-of-function phenotypes
Collapse
Affiliation(s)
| | | | | | - Matilda Males
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Sandra Mueller
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Markus Jabs
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | - Michael Muelleder
- Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK; Molecular Biology of Metabolism Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | - Martin Frejno
- German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
| | | | - Markus Ralser
- Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK; Molecular Biology of Metabolism Laboratory, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
| | | |
Collapse
|
29
|
Rasheed MA, Kantoush N, Abd El-Ghaffar N, Farouk H, Kamel S, Ibrahim AA, Shalaby A, Mahmoud E, Raslan HM, Saleh OM. Expression of JAZF1, ABCC8, KCNJ11and Notch2 genes and vitamin D receptor polymorphisms in type 2 diabetes, and their association with microvascular complications. Ther Adv Endocrinol Metab 2017; 8:97-108. [PMID: 28794851 PMCID: PMC5524251 DOI: 10.1177/2042018817708910] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 04/17/2017] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND We studied JAZF1, ABCC8, KCNJ11and Notch2 gene expression and vitamin D receptor (VDR) polymorphisms (Fok1 and Bsm1) in patients with type 2 diabetes mellitus (T2DM) and tried to find out their association with microvascular complications in these patients. METHODS The study was conducted on 180 patients (93 complicated and 87 noncomplicated) and 150 healthy subjects. Reverse-transcriptase polymerase chain reaction (RT-PCR) was used to assess gene expression and real-time PCR was used to detect VDR genotypes. Serum vitamin D was assessed using Elisa technique. RESULTS After adjustment for age, sex, body mass index and glycated hemoglobin, altered Notch2 gene expression was found between patients and controls and between complicated and noncomplicated cases (p = 0.001 and 0.001, respectively) and ABCC8 gene expression showed significant difference between patients and controls only (p = 0.003), while JAZF1and KCNJ11 expression showed no significant difference between the studied groups (p = 0.3 and 0.4, respectively). Serum vitamin D level was decreased in patients compared with controls (p = 0.001), while no difference was detected between complicated and noncomplicated cases (p = 0.1). Our results revealed no significant difference in VDR Fok1 and Bsm1 genotype distributions (p = 0.7 and 0.1, respectively) and allele frequencies (p = 0.4 and 0.1, respectively) between patients and controls. Patients with complications showed increased frequencies of Fok1GG genotype and G allele, while patients without complications showed increased frequencies of AA, then AG Fok1 genotype and A allele (p = 0.001 and 0.001, respectively). In addition, the frequencies of CC Bsm1 genotype and C allele were significantly higher among patients with complications, while frequencies of TT Bsm1 genotype and T allele were significantly higher among patients without complications (p = 0.02 and 0.003, respectively). CONCLUSION Altered expression of Notch2 and ABCC8 genes may play a role in the pathogenesis of T2DM. Altered expression of Notch2 and VDR polymorphisms may play a role in the development of microvascular complications in diabetic patients. These results may assist in early identification and management of diabetic complications.
Collapse
Affiliation(s)
- Maha A. Rasheed
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Nagwa Kantoush
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Nagwa Abd El-Ghaffar
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Hebatallah Farouk
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Solaf Kamel
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | | | - Aliaa Shalaby
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Eman Mahmoud
- Clinical and Chemical Pathology Department, National Research Centre, Cairo, Egypt
| | - Hala M. Raslan
- Internal Medicine Department, National Research Centre, Cairo, Egypt
| | - Omneya M. Saleh
- Internal Medicine Department, National Research Centre, Cairo, Egypt
| |
Collapse
|
30
|
Tarnowski M, Malinowski D, Safranow K, Dziedziejko V, Pawlik A. HNF1B, TSPAN8 and NOTCH2 gene polymorphisms in women with gestational diabetes. J Matern Fetal Neonatal Med 2017; 31:837-842. [PMID: 28274157 DOI: 10.1080/14767058.2017.1297793] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
PURPOSE To investigate genes involved in pancreatic beta cell function, insulin production and glucose metabolism that may predispose to gestational diabetes mellitus (GDM). METHODS The study group consisted of 204 women with GDM and 207 women with normal glucose tolerance (NGT). The following polymorphisms were genotyped for each patient: HNF1B rs4430796, TSPAN8 rs7961581 and NOTCH2 rs10923931. A p value of <.05 was considered to indicate a statistically significant result. RESULTS There was a statistically significant increase in the frequency of HNF1B rs4430796 G allele among pregnant women with GDM (GG+AG versus AA, OR: 1.55, 95% CI: 1.01-2.36, p = .042; G versus A, OR: 1.39, 95% CI: 1.06-1.83, p = .018), whereas there were no statistically significant differences in the distributions of TSPAN8 rs7961581 and NOTCH2 rs10923931 genotypes and alleles between women with GDM and healthy pregnant women. In the multivariate logistic regression analysis, older age, higher BMI before pregnancy and a higher number of HNF1B rs4430796 G alleles were independent significant predictors of a higher risk of GDM. CONCLUSIONS The results of this study suggest that the HNF1B gene rs4430796 G allele may be associated with increased risk of GDM.
Collapse
Affiliation(s)
- Maciej Tarnowski
- a Department of Physiology , Pomeranian Medical University , Szczecin , Poland
| | - Damian Malinowski
- a Department of Physiology , Pomeranian Medical University , Szczecin , Poland
| | - Krzysztof Safranow
- b Department of Biochemistry and Medical Chemistry , Pomeranian Medical University , Szczecin , Poland
| | - Violetta Dziedziejko
- b Department of Biochemistry and Medical Chemistry , Pomeranian Medical University , Szczecin , Poland
| | - Andrzej Pawlik
- a Department of Physiology , Pomeranian Medical University , Szczecin , Poland
| |
Collapse
|
31
|
Gosadi IM. Assessment of the environmental and genetic factors influencing prevalence of metabolic syndrome in Saudi Arabia. Saudi Med J 2017; 37:12-20. [PMID: 26739969 PMCID: PMC4724673 DOI: 10.15537/smj.2016.1.12675] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Metabolic syndrome (MS) is a combination of factors that increases the risk of cardiovascular atherosclerotic diseases including diabetes, obesity, dyslipidemia, and high blood pressure. Cardiovascular diseases are one of the leading causes of death in the adult Saudi population where the increase in cardiovascular-related mortality is augmented by the rise in the prevalence of MS. Metabolic syndrome is a multi-factorial disorder influenced by interactions between genetic and environmental components. This review aims to provide a comprehensive assessment of studied environmental and genetic factors explaining the prevalence of MS in the Kingdom of Saudi Arabia. Additionally, this review aims to illustrate factors related to the population genetics of Saudi Arabia, which might explain a proportion of the prevalence of MS.
Collapse
Affiliation(s)
- Ibrahim M Gosadi
- Prince Sattam Chair for Epidemiology and Public Health Research, Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. E-mail.
| |
Collapse
|
32
|
Chidambaram M, Liju S, Saboo B, Sathyavani K, Viswanathan V, Pankratz N, Gross M, Mohan V, Radha V. Replication of genome-wide association signals in Asian Indians with early-onset type 2 diabetes. Acta Diabetol 2016; 53:915-923. [PMID: 27488727 DOI: 10.1007/s00592-016-0889-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/20/2016] [Accepted: 07/12/2016] [Indexed: 01/22/2023]
Abstract
AIMS To evaluate the association of 87 genetic variants previously associated with type 2 diabetes mellitus (T2DM) in genome-wide association studies of populations of European ancestry in an Asian Indian population with early-onset type 2 diabetes mellitus (EOT2DM). METHODS The study groups comprised of 877 type 2 diabetes individuals, 436 individuals with EOT2DM (age at diagnosis below 35 years), 441 individuals with older T2DM (diagnosis at 35 years or greater) and controls with normal glucose tolerance (NGT) (n = 400 younger than 35 years; n = 438 older than 35 years). The participants were genotyped for 87 SNPs from 44 genes and 27 intergenic loci. Associations were tested using logistic regression. RESULTS All the variants in TCF7L2 and CDKN2A/2B showed study-wide significance (p < 1.4 × 10-4) with T2DM, but only rs7903146, rs12243326, rs12255372 of TCF7L2 and rs7020996 of CDKN2A/2B showed study-wide significance (p < 1.4 × 10-4) with EOT2DM in this population. In addition, an intergenic SNP on chromosome 1 (rs10493685) was also shown to be study-wide significant (p = 7.1 × 10-6). Several additional SNPs previously associated with T2DM reached borderline significance in this study, but may have been limited by relatively low sample numbers. Various other SNPs of T2DM were not associated with EOT2DM. CONCLUSIONS Some of the variants in TCF7L2 and CDKN2A/2B associated with T2DM are associated with EOT2DM as well. An intergenic SNP on chromosome 1p31 showed association only with early-onset T2DM in this Asian Indian population. The lack of association with many other SNPs of T2DM may be a reflection of the lack of power of the study, sample size, differences in the frequencies of genetic polymorphisms in different ethnic groups, effect sizes, as well as ancestral differences in pattern of LD between the genetic variants involved in early- and late-onset T2DM.
Collapse
Affiliation(s)
- Manickam Chidambaram
- Madras Diabetes Research Foundation, 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
- Division of Cardiovascular Research, Sidra Medical and Research Center, Doha, Qatar
| | - Samuel Liju
- Madras Diabetes Research Foundation, 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
| | - Banshi Saboo
- Diabetologist and Endocrine and Metabolic Physician at Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India
| | - Kumpatla Sathyavani
- M.V. Hospital for Diabetes and Prof. M. Viswanathan Diabetes Research Centre, Chennai, Tamil Nadu, India
| | - Vijay Viswanathan
- M.V. Hospital for Diabetes and Prof. M. Viswanathan Diabetes Research Centre, Chennai, Tamil Nadu, India
| | - Nathan Pankratz
- Department of Laboratory Medicine Pathology, Medical School University of Minnesota, Minneapolis, MN, USA
| | - Myron Gross
- Department of Laboratory Medicine Pathology, Medical School University of Minnesota, Minneapolis, MN, USA
| | - Viswanathan Mohan
- Madras Diabetes Research Foundation, 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India
- Dr. Mohan's Diabetes Specialities Centre, WHO Collaborating Centre for Non-Communicable Diseases Prevention and Control, IDF Centre of Education, Chennai, India
| | - Venkatesan Radha
- Madras Diabetes Research Foundation, 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India.
| |
Collapse
|
33
|
Srivastava A, Mittal B, Prakash J, Srivastava P, Srivastava N, Srivastava N. A multianalytical approach to evaluate the association of 55 SNPs in 28 genes with obesity risk in North Indian adults. Am J Hum Biol 2016; 29. [PMID: 27650258 DOI: 10.1002/ajhb.22923] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 07/13/2016] [Accepted: 08/20/2016] [Indexed: 12/18/2022] Open
Abstract
OBJECTIVES The aim of the study was to investigate the association of 55 SNPs in 28 genes with obesity risk in a North Indian population using a multianalytical approach. METHODS Overall, 480 subjects from the North Indian population were studied using strict inclusion/exclusion criteria. SNP Genotyping was carried out by Sequenom Mass ARRAY platform (Sequenom, San Diego, CA) and validated Taqman® allelic discrimination (Applied Biosystems® ). Statistical analyses were performed using SPSS software version 19.0, SNPStats, GMDR software (version 6) and GENEMANIA. RESULTS Logistic regression analysis of 55 SNPs revealed significant associations (P < .05) of 49 SNPs with BMI linked obesity risk whereas the remaining 6 SNPs revealed no association (P > .05). The pathway-wise G-score revealed the significant role (P = .0001) of food intake-energy expenditure pathway genes. In CART analysis, the combined genotypes of FTO rs9939609 and TCF7L2 rs7903146 revealed the highest risk for BMI linked obesity. The analysis of the FTO-IRX3 locus revealed high LD and high order gene-gene interactions for BMI linked obesity. The interaction network of all of the associated genes in the present study generated by GENEMANIA revealed direct and indirect connections. In addition, the analysis with centralized obesity revealed that none of the SNPs except for FTO rs17818902 were significantly associated (P < .05). CONCLUSIONS In this multi-analytical approach, FTO rs9939609 and IRX3 rs3751723, along with TCF7L2 rs7903146 and TMEM18 rs6548238, emerged as the major SNPs contributing to BMI linked obesity risk in the North Indian population.
Collapse
Affiliation(s)
- Apurva Srivastava
- Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, Uttar Pradesh, 226014, India
| | - Balraj Mittal
- Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, Uttar Pradesh, 226014, India
| | - Jai Prakash
- Department of Physiology, King George's Medical University, Chowk, Lucknow, Uttar Pradesh, 226003, India
| | - Pranjal Srivastava
- Darbhanga Medical College and Hospital Near Karpuri Chowk Benta Laheriasarai Darbhanga, Bihar, 846003, India
| | - Nimisha Srivastava
- Sikkim Manipal Institute of Medical Sciences (SMIMS), National Highway 31A, Upper Tadong, Gangtok, 737102, Sikkim
| | - Neena Srivastava
- Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, Uttar Pradesh, 226014, India
| |
Collapse
|
34
|
Artunc-Ulkumen B, Ulucay S, Pala HG, Cam S. Maternal serum ADAMTS-9 levels in gestational diabetes: a pilot study. J Matern Fetal Neonatal Med 2016; 30:1442-1445. [PMID: 27485821 DOI: 10.1080/14767058.2016.1219717] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE Gestational diabetes mellitus (GDM) is characterized with insulin resistance which is diagnosed during pregnancy. Although pregnancy is a diabetogenic state, not all women develop GDM. Genetic factors together with enviromental factors cause the maladaptation of maternal pancreas to this diabetogenic state and GDM develops. ADAMTS-9 is a recently recognized molecule whose genetic variants have risk of GDM. Decreased levels have already been shown in fetal membranes. Maternal serum levels of this protein have not been studied yet. We hypothesized that the alteration of ADAMTS-9 expression should cause changes in maternal serum levels which further could help to identify the disease and develop new treatment strategies. MATERIALS AND METHODS This prospective case-control study is consisted of 27 pregnancies with GDM and 30 healthy singleton pregnancies matched for matenal age, gestational week, and maternal weight. GDM diagnosis was made with 2-h 75 g oral glucose tolerance test. ADAMTS-9 levels were compared between groups. RESULTS ADAMTS levels were 3.62 ± 0.33 ng/dL (range: 3.04-4.23) in GDM group and 4.65 ± 1.70 ng/dL (range: 3.07-8.21) in control group (p < 0.001). ADAMTS levels were not affected by maternal age, gestational age, and maternal weight. CONCLUSION ADAMTS-9 levels were significantly lower in GDM pregnancies. This may help to understand the mechanism of GDM pathogenesis. In future, target treatments with ADAMTS proteins may help to improve the severity of diabetes pathogenesis.
Collapse
Affiliation(s)
- Burcu Artunc-Ulkumen
- a School of Medicine, Department of Obstetrics and Gynecology, Celal Bayar University , Manisa , Turkey and
| | - Safiye Ulucay
- b School of Medicine, Department of Medical Genetics, Celal Bayar University , Manisa , Turkey
| | - Halil Gursoy Pala
- a School of Medicine, Department of Obstetrics and Gynecology, Celal Bayar University , Manisa , Turkey and
| | - Sirri Cam
- b School of Medicine, Department of Medical Genetics, Celal Bayar University , Manisa , Turkey
| |
Collapse
|
35
|
Gadelha A, Coleman J, Breen G, Mazzoti DR, Yonamine CM, Pellegrino R, Ota VK, Belangero SI, Glessner J, Sleiman P, Hakonarson H, Hayashi MAF, Bressan RA. Genome-wide investigation of schizophrenia associated plasma Ndel1 enzyme activity. Schizophr Res 2016; 172:60-7. [PMID: 26851141 DOI: 10.1016/j.schres.2016.01.043] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Revised: 01/19/2016] [Accepted: 01/23/2016] [Indexed: 10/22/2022]
Abstract
Ndel1 is a DISC1-interacting oligopeptidase that cleaves in vitro neuropeptides as neurotensin and bradykinin, and which has been associated with both neuronal migration and neurite outgrowth. We previously reported that plasma Ndel1 enzyme activity is lower in patients with schizophrenia (SCZ) compared to healthy controls (HCs). To our knowledge, no previous study has investigated the genetic factors associated with the plasma Ndel1 enzyme activity. In the current analyses, samples from 83 SCZ patients and 92 control subjects that were assayed for plasma Ndel1 enzyme activity were genotyped on Illumina Omni Express arrays. A genetic relationship matrix using genome-wide information was then used for ancestry correction, and association statistics were calculated genome-wide. Ndel1 enzyme activity was significantly lower in patients with SCZ (t=4.9; p<0.001) and was found to be associated with CAMK1D, MAGI2, CCDC25, and GABGR3, at a level of suggestive significance (p<10(-6)), independent of the clinical status. Then, we performed a model to investigate the observed differences for case/control measures. 2 SNPs at region 1p22.2 reached the p<10(-7) level. ZFPM2 and MAD1L1 were the only two genes with more than one hit at 10(-6) order of p value. Therefore, Ndel1 enzyme activity is a complex trait influenced by many different genetic variants that may contribute to SCZ physiopathology.
Collapse
Affiliation(s)
- Ary Gadelha
- Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, Brazil.
| | - Jonathan Coleman
- Medical Research Council Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Gerome Breen
- Medical Research Council Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry Psychology and Neuroscience, King's College London, London, United Kingdom; National Institute of Health Research Biomedical Research Centre for Mental Health, Maudsley Hospital and Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom
| | | | - Camila M Yonamine
- Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, Brazil; Department of Pharmacology, UNIFESP/EPM, São Paulo, Brazil
| | - Renata Pellegrino
- Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, United States
| | - Vanessa Kiyomi Ota
- Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, Brazil; Department of Morphology and Genetics, UNIFESP/EPM, São Paulo, Brazil
| | - Sintia Iole Belangero
- Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, Brazil; Department of Morphology and Genetics, UNIFESP/EPM, São Paulo, Brazil
| | - Joseph Glessner
- Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, United States
| | - Patrick Sleiman
- Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, United States; Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | - Hakon Hakonarson
- Center for Applied Genomics, The Children's Hospital of Philadelphia, Philadelphia, United States; Department of Pediatrics, The Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
| | | | - Rodrigo A Bressan
- Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP/EPM), São Paulo, Brazil
| |
Collapse
|
36
|
The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. J Gastroenterol 2016; 51:370-9. [PMID: 26337813 DOI: 10.1007/s00535-015-1116-6] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 08/14/2015] [Indexed: 02/04/2023]
Abstract
BACKGROUND Type 2 diabetes mellitus (T2DM) is an established independent risk factor for hepatocellular carcinoma (HCC). T2DM is associated with non-alcoholic steatohepatitis (NASH), which is a major cause of non-HBV and non-HCV-related HCC; nevertheless, it has been difficult to identify those patients with T2DM who have a high risk of developing HCC. The aim of this study was to identify genetic determinants that predispose T2DM patients to HCC by genotyping T2DM susceptibility loci and PNPLA3. METHODS We recruited 389 patients with T2DM who satisfied the following three criteria: negative for HBs-Ag and anti-HCV Ab, alcohol intake <60 g/day, and history of T2DM >10 years. These patients were divided into two groups: T2DM patients with HCC (DM-HCC, n = 59) or those without HCC (DM-non-HCC, n = 330). We genotyped 51 single-nucleotide polymorphisms (SNPs) previously reported as T2DM or NASH susceptibility loci (PNPLA3) compared between the DM-HCC and DM-non-HCC groups with regard to allele frequencies at each SNP. RESULTS The SNP rs738409 located in PNPLA3 was the greatest risk factor associated with HCC. The frequency of the PNPLA3 G allele was significantly higher among DM-HCC individuals than DM-non-HCC individuals (OR 2.53, p = 1.05 × 10(-5)). Among individuals homozygous for the PNPLA3 G allele (n = 115), the frequency of the JAZF1 rs864745 G allele was significantly higher among DM-HCC individuals than DM-non-HCC individuals (OR 3.44, p = 0.0002). CONCLUSIONS PNPLA3 and JAZF1 were associated with non-HBV and non-HCV-related HCC development among Japanese patients with T2DM.
Collapse
|
37
|
Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SEH, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer 2015; 22:545-59. [PMID: 26099684 DOI: 10.1530/erc-15-0029] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 05/15/2015] [Indexed: 12/18/2022]
Abstract
Type 2 diabetes (T2D) has been suggested to be a risk factor for multiple myeloma (MM), but the relationship between the two traits is still not well understood. The aims of this study were to evaluate whether 58 genome-wide-association-studies (GWAS)-identified common variants for T2D influence the risk of developing MM and to determine whether predictive models built with these variants might help to predict the disease risk. We conducted a case-control study including 1420 MM patients and 1858 controls ascertained through the International Multiple Myeloma (IMMEnSE) consortium. Subjects carrying the KCNQ1rs2237892T allele or the CDKN2A-2Brs2383208G/G, IGF1rs35767T/T and MADDrs7944584T/T genotypes had a significantly increased risk of MM (odds ratio (OR)=1.32-2.13) whereas those carrying the KCNJ11rs5215C, KCNJ11rs5219T and THADArs7578597C alleles or the FTOrs8050136A/A and LTArs1041981C/C genotypes showed a significantly decreased risk of developing the disease (OR=0.76-0.85). Interestingly, a prediction model including those T2D-related variants associated with the risk of MM showed a significantly improved discriminatory ability to predict the disease when compared to a model without genetic information (area under the curve (AUC)=0.645 vs AUC=0.629; P=4.05×10(-) (06)). A gender-stratified analysis also revealed a significant gender effect modification for ADAM30rs2641348 and NOTCH2rs10923931 variants (Pinteraction=0.001 and 0.0004, respectively). Men carrying the ADAM30rs2641348C and NOTCH2rs10923931T alleles had a significantly decreased risk of MM whereas an opposite but not significant effect was observed in women (ORM=0.71 and ORM=0.66 vs ORW=1.22 and ORW=1.15, respectively). These results suggest that TD2-related variants may influence the risk of developing MM and their genotyping might help to improve MM risk prediction models.
Collapse
Affiliation(s)
- Rafael Ríos
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Carmen Belén Lupiañez
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Daniele Campa
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Alessandro Martino
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Joaquin Martínez-López
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Manuel Martínez-Bueno
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Judit Varkonyi
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Ramón García-Sanz
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Krzysztof Jamroziak
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Charles Dumontet
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Andrés Jerez Cayuela
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Marzena Wętek
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Stephano Landi
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Anna Maria Rossi
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Fabienne Lesueur
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Rui Manuel Reis
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Victor Moreno
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Herlander Marques
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Artur Jurczyszyn
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Vibeke Andersen
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Ulla Vogel
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Gabriele Buda
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Enrico Orciuolo
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Svend E H Jacobsen
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Mario Petrini
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Annette J Vangsted
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Federica Gemignani
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Federico Canzian
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark
| | - Manuel Jurado
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| | - Juan Sainz
- Genomic Oncology AreaGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, 18016 Granada, SpainHematology DepartmentVirgen de las Nieves University Hospital, Granada, SpainGenomic Epidemiology GroupGerman Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of BiologyUniversity of Pisa, Pisa, ItalyDepartment of HematologyHospital Universitario Doce de Octubre, Madrid, SpainArea of Genomic MedicineGENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Granada, SpainSemmelweis UniversityBudapest, HungaryHaematology DepartmentUniversity Hospital of Salamanca and IBSAL, Salamanca, SpainMedical University of LodzLodz, PolandINSERM UMR 1052/CNRS 5286Université Claude Bernard Lyon I, Lyon, FranceMorales Meseguer General University HospitalMurcia, SpainHaematoloy ClinikHolly Cross Cancer Center, Kielce, PolandINSERMU900, Genetic Epidemiology of Cancers team, Institut Curie, Mines ParisTech, Paris, FranceLife and Health Sciences Research Institute (ICVS)School of Health Sciences, University of Minho, Braga, PortugalICVS/3B's - PT Government Associate LaboratoryBraga/Guimarães, PortugalMolecular Oncology Research CenterBarretos Cancer Hospital, Barretos, BrazilIDIBELL - Catalan Institute of OncologyUniversity of Barcelona, Barcelona 08907, SpainDepartment of HematologyCracow University Hospital, Cracow, PolandOrgan CenterHospital of Southern Jutland, DK-6200 Aabenraa, DenmarkFaculty of Health SciencesInstitute of Regional Health Research, University of Southern Denmark, DK-5000 Odense C, DenmarkUO HematologyDepartment of Internal and Experimental Medicine, University of Pisa, Pisa, ItalyClinic of Biochemistry and ImmunologyLaboratory Center, Hospital of Southern Jutland, Aabenraa, DenmarkDepartment of HaematologyRigshospitalet and Roskilde Hospital, Copenhagen University, Copenhagen, Denmark Genomic Oncology AreaGENYO, Cen
| |
Collapse
|
38
|
Yoshina S, Mitani S. Loss of C. elegans GON-1, an ADAMTS9 Homolog, Decreases Secretion Resulting in Altered Lifespan and Dauer Formation. PLoS One 2015. [PMID: 26218657 PMCID: PMC4517882 DOI: 10.1371/journal.pone.0133966] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
ADAMTS9 is a metalloprotease that cleaves components of the extracellular matrix and is also implicated in transport from the endoplasmic reticulum (ER) to the Golgi. It has been reported that an ADAMTS9 gene variant is associated with type 2 diabetes. The underlying pathology of type 2 diabetes is insulin resistance and beta-cell dysfunction. However, the molecular mechanisms underlying ADAMTS9 function in beta cells and peripheral tissues are unknown. We show that loss of C. elegans GON-1, an ADAMTS9 homolog, alters lifespan and dauer formation. GON-1 loss impairs secretion of proteins such as insulin orthologs and TGF-beta, and additionally impacts insulin/IGF-1 signaling in peripheral tissues. The function of the GON domain, but not the protease domain, is essential for normal lifespan and dauer formation in these scenarios. We conclude that the GON domain is critical for ADAMTS9/GON-1 function across species, which should help the understanding of type 2 diabetes in humans.
Collapse
Affiliation(s)
- Sawako Yoshina
- Department of Physiology, Tokyo Women’s Medical University School of Medicine, Tokyo, 162–8666, Japan
| | - Shohei Mitani
- Department of Physiology, Tokyo Women’s Medical University School of Medicine, Tokyo, 162–8666, Japan
- Tokyo Women’s Medical University Institute for Integrated Medical Sciences (TIIMS), Tokyo Women’s Medical University, Tokyo, 162–8666, Japan
- * E-mail:
| |
Collapse
|
39
|
Yuasa K, Aoki N, Hijikata T. JAZF1 promotes proliferation of C2C12 cells, but retards their myogenic differentiation through transcriptional repression of MEF2C and MRF4-Implications for the role of Jazf1 variants in oncogenesis and type 2 diabetes. Exp Cell Res 2015; 336:287-97. [PMID: 26101156 DOI: 10.1016/j.yexcr.2015.06.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Revised: 06/09/2015] [Accepted: 06/15/2015] [Indexed: 11/16/2022]
Abstract
Single-nucleotide polymorphisms associated with type 2 diabetes (T2D) have been identified in Jazf1, which is also involved in the oncogenesis of endometrial stromal tumors. To understand how Jazf1 variants confer a risk of tumorigenesis and T2D, we explored the functional roles of JAZF1 and searched for JAZF1 target genes in myogenic C2C12 cells. Consistent with an increase of Jazf1 transcripts during myoblast proliferation and their decrease during myogenic differentiation in regenerating skeletal muscle, JAZF1 overexpression promoted cell proliferation, whereas it retarded myogenic differentiation. Examination of myogenic genes revealed that JAZF1 overexpression transcriptionally repressed MEF2C and MRF4 and their downstream genes. AMP deaminase1 (AMPD1) was identified as a candidate for JAZF1 target by gene array analysis. However, promoter assays of Ampd1 demonstrated that mutation of the putative binding site for the TR4/JAZF1 complex did not alleviate the repressive effects of JAZF1 on promoter activity. Instead, JAZF1-mediated repression of Ampd1 occurred through the MEF2-binding site and E-box within the Ampd1 proximal regulatory elements. Consistently, MEF2C and MRF4 expression enhanced Ampd1 promoter activity. AMPD1 overexpression and JAZF1 downregulation impaired AMPK phosphorylation, while JAZF1 overexpression also reduced it. Collectively, these results suggest that aberrant JAZF1 expression contributes to the oncogenesis and T2D pathogenesis.
Collapse
Affiliation(s)
- Katsutoshi Yuasa
- Department of Anatomy and Cell Biology, Research Institute of Pharmaceutical Science, Faculty of Pharmacy, Musashino University, Nishitokyo, Tokyo 202-8585, Japan
| | - Natsumi Aoki
- Department of Anatomy and Cell Biology, Research Institute of Pharmaceutical Science, Faculty of Pharmacy, Musashino University, Nishitokyo, Tokyo 202-8585, Japan
| | - Takao Hijikata
- Department of Anatomy and Cell Biology, Research Institute of Pharmaceutical Science, Faculty of Pharmacy, Musashino University, Nishitokyo, Tokyo 202-8585, Japan.
| |
Collapse
|
40
|
Song M, Zhao F, Ran L, Dolikun M, Wu L, Ge S, Dong H, Gao Q, Zhai Y, Zhang L, Yan Y, Liu F, Yang X, Guo X, Wang Y, Wang W. The Uyghur population and genetic susceptibility to type 2 diabetes: potential role for variants in CDKAL1, JAZF1, and IGF1 genes. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY 2015; 19:230-7. [PMID: 25785549 DOI: 10.1089/omi.2014.0162] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Substantial evidence suggests that type 2 diabetes mellitus (T2DM) is a multi-factorial disease with a strong genetic component. A list of genetic susceptibility loci in populations of European and Asian ancestry has been established in the literature. Little is known on the inter-ethnic contribution of such established functional polymorphic variants. We performed a case-control study to explore the genetic susceptibility of 16 selected T2DM-related SNPs in a cohort of 102 Uyghur objects (51 cases and 51 controls). Three of the 16 SNPs showed significant association with T2DM in the Uyghur population. There were significant differences between the T2DM and control groups in frequencies of the risk allelic distributions of rs7754840 (CDKAL1) (p=0.014), rs864745 (JAZF1) (p=0.032), and rs35767 (IGF1) (p=0.044). Carriers of rs7754840-C, rs35767-A, and rs864745-C risk alleles had a 2.32-fold [OR (95% CI): 1.19-4.54], 2.06-fold [OR (95% CI): 1.02-4.17], 0.48-fold [OR (95% CI): 0.24-0.94] increased risk for T2DM, respectively. The cumulative risk allelic scores of these 16 SNPs differed significantly between the T2DM patients and the controls [17.1±8.1 vs. 15.4±7.3; OR (95%CI): 1.27(1.07-1.50), p=0.007]. This is the first study to evaluate genomic variation at 16 SNPs in respective T2DM candidate genes for the Uyghur population compared with other ethnic groups. The SNP rs7754840 in CDKAL1, rs864745 in JAZF1, and rs35767 in IGF1 might serve as potential susceptibility loci for T2DM in Uyghurs. We suggest a broader capture and study of the world populations, including who that are hitherto understudied, are essential for a comprehensive understanding of the genetic/genomic basis of T2DM.
Collapse
Affiliation(s)
- Manshu Song
- 1 School of Public Health, Capital Medical University , Beijing, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel) 2015; 6:87-123. [PMID: 25774817 PMCID: PMC4377835 DOI: 10.3390/genes6010087] [Citation(s) in RCA: 279] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Revised: 01/28/2015] [Accepted: 02/27/2015] [Indexed: 12/11/2022] Open
Abstract
Type 2 diabetes (T2D) is a complex disease that is caused by a complex interplay between genetic, epigenetic and environmental factors. While the major environmental factors, diet and activity level, are well known, identification of the genetic factors has been a challenge. However, recent years have seen an explosion of genetic variants in risk and protection of T2D due to the technical development that has allowed genome-wide association studies and next-generation sequencing. Today, more than 120 variants have been convincingly replicated for association with T2D and many more with diabetes-related traits. Still, these variants only explain a small proportion of the total heritability of T2D. In this review, we address the possibilities to elucidate the genetic landscape of T2D as well as discuss pitfalls with current strategies to identify the elusive unknown heritability including the possibility that our definition of diabetes and its subgroups is imprecise and thereby makes the identification of genetic causes difficult.
Collapse
Affiliation(s)
- Rashmi B Prasad
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, CRC, Skåne University Hospital SUS, SE-205 02 Malmö, Sweden.
| | - Leif Groop
- Department of Clinical Sciences, Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, CRC, Skåne University Hospital SUS, SE-205 02 Malmö, Sweden.
- Finnish Institute of Molecular Medicine (FIMM), Helsinki University, Helsinki 00014, Finland.
| |
Collapse
|
42
|
Alharbi KK, Ali Khan I, Syed R, Alharbi FK, Mohammed AK, Vinodson B, Al-Daghri NM. Association of JAZF1 and TSPAN8/LGR5 variants in relation to type 2 diabetes mellitus in a Saudi population. Diabetol Metab Syndr 2015; 7:92. [PMID: 26500707 PMCID: PMC4619989 DOI: 10.1186/s13098-015-0091-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Accepted: 10/15/2015] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Type 2 diabetes mellitus (T2DM) is a chronic and multifactorial disease with a rapidly rising incidence in Saudi Arabia. Various genes including zinc finger protein 1 (JAZF1) and tetraspanin 8/leucine-rich repeat-containing G protein-coupled receptor (TSPAN8/LGR5) have been previously described to be associated with T2DM. This study investigated the association of JAZF1 (rs864745) and TSPAN8 (rs7961581) with T2DM in a Saudi population. METHODS Genomic DNA samples from 400 Saudi T2DM patients and 400 healthy controls were genotyped and analyzed using a polymerase chain reaction-restriction fragment length polymorphism method. The difference between the genotype frequencies were carried out with Chi-square test. Odds ratio, 95 % confidence intervals and p values were calculated using multinomial logistic regression. Dominant and recessive models were implemented to show the statistical significances. Analysis of variance was used to compare differences between genotypes for the various parameters. RESULTS Distribution frequencies of the AA, AG, and GG genotypes of JAZF1 (rs864745) differed significantly among T2DM patients and healthy controls (p < 0.05). The AG and GG genotypes were independently and significantly associated with a T2DM risk after adjusting for factors such as age, sex, and body mass index [odds ratio (OR) 2.1 (95 % confidence interval (CI) 1.3-3.4); p = 0.002] and [OR 1.9 (95 % CI 1.2-3.1); p = 0.005], respectively. A genotype-based stratification of anthropometric and biochemical data revealed that the AG + GG genotype is associated with waist circumference (p = 0.04) and fasting blood glucose (p = 0.01) and high-density lipoprotein cholesterol levels (p = 0.02). None of the allele or genotype showed the significant association between the T2DM cases and control subjects in rs7961581 polymorphism in TSPAN8/LGR5 gene. CONCLUSION The rs864745 variant in JAZF1 gene may act as genetic risk factors for the development of T2DM in a Saudi population.
Collapse
Affiliation(s)
- Khalid Khalaf Alharbi
- />Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh, 11433 Kingdom of Saudi Arabia
| | - Imran Ali Khan
- />Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh, 11433 Kingdom of Saudi Arabia
| | - Rabbani Syed
- />Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh, 11433 Kingdom of Saudi Arabia
| | - Fawiziah Khalaf Alharbi
- />Department of Biology Science, College of Science and Arts, Al-Qassim University, PO Box 1300, Buraidah, 51431 Kingdom of Saudi Arabia
| | - Abdul Khader Mohammed
- />Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, 11451 Saudi Arabia
- />Biomarkers Research Program, Department of Biochemistry, College of Science, King Saud University, Riyadh, 11451 Saudi Arabia
| | - Benjamin Vinodson
- />Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, 11451 Saudi Arabia
| | - Nasser M. Al-Daghri
- />Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, 11451 Saudi Arabia
- />Biomarkers Research Program, Department of Biochemistry, College of Science, King Saud University, Riyadh, 11451 Saudi Arabia
| |
Collapse
|
43
|
Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: the IMMEDIATE trial. THE PHARMACOGENOMICS JOURNAL 2014; 15:55-62. [PMID: 25135348 DOI: 10.1038/tpj.2014.41] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Revised: 04/29/2014] [Accepted: 06/04/2014] [Indexed: 11/09/2022]
Abstract
The mechanistic effects of intravenous glucose, insulin and potassium (GIK) in cardiac ischemia are not well understood. We conducted a genetic sub-study of the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial to explore effects of common and rare glucose and insulin-related genetic loci on initial to 6-h and 6- to 12-h change in plasma glucose and potassium. We identified 27 NOTCH2/ADAM30 and 8 C2CD4B variants conferring a 40-57% increase in glucose during the first 6 h of infusion (P<5.96 × 10(-6)). Significant associations were also found for ABCB11 and SLC30A8 single-nucleotide polymorphisms (SNPs) and glucose responses, and an SEC61A2 SNP with a potassium response to GIK. These studies identify genetic factors that may impact the metabolic response to GIK, which could influence treatment benefits in the setting of acute coronary syndromes (ACS).
Collapse
|
44
|
Ming GF, Li X, Yin JY, Ai YH, Xu DM, Ma XH, Liu ZY, Liu HX, Zhou HH, Liu ZQ. JAZF1 regulates visfatin expression in adipocytes via PPARα and PPARβ/δ signaling. Metabolism 2014; 63:1012-21. [PMID: 24930994 DOI: 10.1016/j.metabol.2014.05.006] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2013] [Revised: 04/20/2014] [Accepted: 05/11/2014] [Indexed: 11/17/2022]
Abstract
OBJECTIVE Current whole genome-wide association study has identified the association of JAZF1 with type 2 diabetes; its close relation with glucose and lipid metabolism has also been revealed. However, to date, JAZF1 remains a relatively new gene with unknown function. MATERIALS/METHODS We constructed JAZF1 overexpression vector and synthesized JAZF1 siRNA, then transfected them into 3T3-L1 adipocytes, investigated the relationship between the regulations of JAZF1, visfatin, and other adipokines, researched the specific function of JAZF1 in glucose and lipid metabolism. RESULTS This study found that the expression of JAZF1 was gradually but significantly upregulated during the induced differentiation of 3T3-L1 preadipocytes, and that the trend of its expression was consistent with that of visfatin. Further studies indicated that JAZF1 promoted the expressions of visfatin, PPARα, and PPARβ/δ in adipocytes but simultaneously inhibited the expressions of TAK1 and PPARγ. Luciferase reporter assay revealed that JAZF1 activated the transcription of visfatin, but ChIP assay results indicated that JAZF1 did not directly bind to visfatin PPRE. Our results also showed that the JAZF1 overexpression-increased visfatin expression was abolished by the addition of PPARα antagonist GW 6471 and PPARβ/δ antagonist GSK 3787 respectively. And these results were further confirmed by the experiment with PPARα and PPARβ/δ siRNAs. Meanwhile, we also found that JAZF1 inhibited the lipid accumulation during the differentiation of 3T3-L1 into mature adipocyte. CONCLUSIONS Our results indicate that JAZF1 might firstly upregulated the expression of PPARα and PPARβ/δ, which in turn activated the transcription of visfatin. JAZF1 plays an important role in lipid metabolism and may thus provide a potential tool for the treatment of obesity and lipid metabolism disorders among other diseases.
Collapse
Affiliation(s)
- Guang-feng Ming
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078; P. R. China; Department of critical care medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Xi Li
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078; P. R. China
| | - Ji-ye Yin
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078; P. R. China
| | - Yu-hang Ai
- Department of critical care medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Dao-miao Xu
- Department of critical care medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Xin-hua Ma
- Department of critical care medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Zhi-yong Liu
- Department of critical care medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Hui-xia Liu
- Department of Geriatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Hong-hao Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078; P. R. China
| | - Zhao-qian Liu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078; P. R. China.
| |
Collapse
|
45
|
Ozler S, Demircan K. The investigation of the role of proteoglycans and ADAMTS levels in fetal membranes in physiopathological process of gestational diabetes. Med Hypotheses 2014; 104:182-184. [PMID: 25047995 DOI: 10.1016/j.mehy.2014.06.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Accepted: 06/26/2014] [Indexed: 01/01/2023]
Abstract
About 2-5% of all pregnant women develop gestational diabetes mellitus (GDM) during pregnancy and its prevalence has increased markedly within the last decade. GDM is a metabolic syndrome produced by various degrees of carbohydrate intolerance during pregnancy. Various risk factors such as obesity, genetics, environmental factors, and hypertension have been described previously. Maternal and fetal complications occur in around 7% of pregnant women with GDM. In these patients, a relation between proteoglycans and ADAMTS proteases located in extracellular matrix in fetal membranes (placenta, cord, amnion) and complicated pregnancies has already been determined by various animal experiments. Changes in expression, structure and function of ADAMTS proteases and proteoglycans in fetal membranes lead to alteration in the structure of extracellular matrix. If we can establish a balance between these proteoglycans and ADMTS proteases or determine the changes in their structure and functions, it will be possible to predict the risk in high risk pregnancies at early weeks and to initiate treatment early or to follow the target population regularly. In addition, prevention or reduction of maternal and fetal complications may be possible. For this purpose, ADAMTS and proteoglycans the synthesis of which is too much or less, may be targeted and if we would be able to determine and prevent the changes in their levels in the early period of pregnancy, the development of GDM and its complications may be prevented or decreased. Thus, we may identify a marker for early diagnosis and treatment and reduce prematurity, which is the most common cause of fetal death. Fetal and maternal complications, and especially treatment and care costs of prematurity, may also be decreased.
Collapse
Affiliation(s)
- Sibel Ozler
- Zekai Tahir Burak Women's Health Education and Research Hospital, Talatpasa Street, 06230 Samanpazarı, Ankara, Turkey.
| | - Kadir Demircan
- Turgut Ozal University Faculty of Medicine, Medical Genetics Department, Anadolu Street 16/A, 06210 Yenimahalle, Ankara, Turkey
| |
Collapse
|
46
|
Ben-Shlomo I, Younis JS. Basic research in PCOS: are we reaching new frontiers? Reprod Biomed Online 2014; 28:669-83. [DOI: 10.1016/j.rbmo.2014.02.011] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2013] [Revised: 12/21/2013] [Accepted: 02/12/2014] [Indexed: 01/05/2023]
|
47
|
Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application. BIOMED RESEARCH INTERNATIONAL 2014; 2014:926713. [PMID: 24864266 PMCID: PMC4016836 DOI: 10.1155/2014/926713] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Accepted: 03/22/2014] [Indexed: 02/06/2023]
Abstract
With rapidly increasing prevalence, diabetes has become one of the major causes of mortality worldwide. According to the latest studies, genetic information makes substantial contributions towards the prediction of diabetes risk and individualized antidiabetic treatment. To date, approximately 70 susceptibility genes have been identified as being associated with type 2 diabetes (T2D) at a genome-wide significant level (P < 5 × 10−8). However, all the genetic loci identified so far account for only about 10% of the overall heritability of T2D. In addition, how these novel susceptibility loci correlate with the pathophysiology of the disease remains largely unknown. This review covers the major genetic studies on the risk of T2D based on ethnicity and briefly discusses the potential mechanisms and clinical utility of the genetic information underlying T2D.
Collapse
|
48
|
Ren Q, Han X, Tang Y, Zhang X, Zou X, Cai X, Zhang S, Zhang L, Li H, Ji L. Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. Diabetologia 2014; 57:746-53. [PMID: 24356749 DOI: 10.1007/s00125-013-3146-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2013] [Accepted: 11/27/2013] [Indexed: 01/10/2023]
Abstract
AIMS/HYPOTHESIS The aim of this study was to investigate whether genetic variance can influence the efficacy of glibenclamide in patients with type 2 diabetes. METHODS A total of 747 patients with type 2 diabetes was enrolled from the Xiaoke Pills Clinical Trial, which is a double-blind, randomised controlled trial. All the patients had been treated with glibenclamide for 48 weeks, with strict drug dose adjustment and data collection. Treatment failure was confirmed when patients reached the criteria for terminating their participation in the study (fasting blood glucose level ≥ 7.0 mmol/l on two consecutive tests 4 weeks after reaching the pre-set maximal dose or maximal tolerated dose). Using this cohort, we tested 44 single-nucleotide polymorphisms (SNPs) in 27 gene regions. The genes in our study were involved in the metabolism of sulfonylureas, islet beta cell function, insulin resistance and beta cell growth and differentiation. A logistic regression model was used to evaluate the relationship between genetic variants and treatment failure over a period of 48 weeks. RESULTS We found that no SNP reached the significance level of p < 0.00125 if Bonferroni correction was performed for multiple testing in the logistic regression model used in this pharmacogenetic study. Participants with the minor allele C of rs10811661 in CDKN2A/CDKN2B showed a significantly greater reduction in fasting blood glucose (TT vs TC vs CC: 9.3% (0-20.0%) vs 9.2% (0.9-20.5%) vs 12.7% (5.2-24.4%), p = 0.008) after the initial 4 weeks of treatment independent of age, sex and BMI. There was a significant difference in beta cell function among carriers of different genotypes of rs10811661. CONCLUSIONS/INTERPRETATION Our study demonstrated that the CDKN2A/CDKN2B gene may be nominally associated with the efficacy of glibenclamide, and that CDKN2A/CDKN2B is associated with beta cell function.
Collapse
Affiliation(s)
- Qian Ren
- Department of Endocrinology and Metabolism, Peking University People's Hospital, No. 11, Xizhimen South Street, Beijing, 100044, People's Republic of China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Ming GF, Xiao D, Gong WJ, Liu HX, Liu J, Zhou HH, Liu ZQ. JAZF1 can regulate the expression of lipid metabolic genes and inhibit lipid accumulation in adipocytes. Biochem Biophys Res Commun 2014; 445:673-80. [PMID: 24583129 DOI: 10.1016/j.bbrc.2014.02.088] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 02/20/2014] [Indexed: 01/15/2023]
Abstract
JAZF1 is a newly identified gene with unknown functions. A recent genome-wide association study showed that JAZF1 is associated with type 2 diabetes and is highly expressed in liver and adipose tissue. Studies have demonstrated that JAZF1 is the co-repressor for nuclear orphan receptor TAK1, whereas most nuclear orphan receptor family members are involved in the regulation of lipid metabolism. Therefore, JAZF1 could be closely related to glycolipid metabolism. In this study, JAZF1 was significantly upregulated during the induced differentiation process of 3T3-L1 preadipocytes. The overexpression of JAZF1 inhibited lipid accumulation in differentiated mature 3T3-L1 adipocytes and significantly inhibited the expression of SREBPl, ACC, and FAS, which were important in lipid synthesis, while upregulating the expression of key enzyme hormone-sensitive lipase in lipoclasis. Moreover, SREBPl exhibited an inhibitory function on the expression of JAZF1. SREBP1 reversed the inhibitory action on lipid accumulation of JAZF1. SREBP1 and JAZF1 were observed to regulate each other in adipocytes. Therefore, JAZF1 could regulate the expression of particular genes related to lipid metabolism and inhibit lipid accumulation in adipocytes. This result suggests that JAZF1 may be a potential target for the treatment of diseases, such as obesity and lipid metabolism disorders.
Collapse
Affiliation(s)
- Guang-feng Ming
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, Hunan, China; Department of Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Di Xiao
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, Hunan, China
| | - Wei-jing Gong
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, Hunan, China
| | - Hui-xia Liu
- Department of Geriatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Jun Liu
- Department of Geriatrics, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
| | - Hong-hao Zhou
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, Hunan, China
| | - Zhao-qian Liu
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, Hunan, China.
| |
Collapse
|
50
|
Abdullah N, Attia J, Oldmeadow C, Scott RJ, Holliday EG. The architecture of risk for type 2 diabetes: understanding Asia in the context of global findings. Int J Endocrinol 2014; 2014:593982. [PMID: 24744783 PMCID: PMC3976842 DOI: 10.1155/2014/593982] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2013] [Accepted: 01/30/2014] [Indexed: 02/07/2023] Open
Abstract
The prevalence of Type 2 diabetes is rising rapidly in both developed and developing countries. Asia is developing as the epicentre of the escalating pandemic, reflecting rapid transitions in demography, migration, diet, and lifestyle patterns. The effective management of Type 2 diabetes in Asia may be complicated by differences in prevalence, risk factor profiles, genetic risk allele frequencies, and gene-environment interactions between different Asian countries, and between Asian and other continental populations. To reduce the worldwide burden of T2D, it will be important to understand the architecture of T2D susceptibility both within and between populations. This review will provide an overview of known genetic and nongenetic risk factors for T2D, placing the results from Asian studies in the context of broader global research. Given recent evidence from large-scale genetic studies of T2D, we place special emphasis on emerging knowledge about the genetic architecture of T2D and the potential contribution of genetic effects to population differences in risk.
Collapse
Affiliation(s)
- Noraidatulakma Abdullah
- School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Newcastle, NSW 2308, Australia
- UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
| | - John Attia
- Clinical Research Design, IT and Statistical Support (CReDITSS) Unit, Hunter Medical Research Institute, Newcastle, NSW 2305, Australia
- Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health, University of Newcastle, Newcastle, NSW 2305, Australia
| | - Christopher Oldmeadow
- Clinical Research Design, IT and Statistical Support (CReDITSS) Unit, Hunter Medical Research Institute, Newcastle, NSW 2305, Australia
- Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health, University of Newcastle, Newcastle, NSW 2305, Australia
| | - Rodney J. Scott
- School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Newcastle, NSW 2308, Australia
- Hunter Area Pathology Service, John Hunter Hospital, Newcastle, NSW 2305, Australia
| | - Elizabeth G. Holliday
- Clinical Research Design, IT and Statistical Support (CReDITSS) Unit, Hunter Medical Research Institute, Newcastle, NSW 2305, Australia
- Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, Faculty of Health, University of Newcastle, Newcastle, NSW 2305, Australia
- *Elizabeth G. Holliday:
| |
Collapse
|